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1. Introduction 
This report describes the results of a proficiency test defined as External Quality Assurance System 
(EQAS) 2011 for antimicrobial susceptibility testing (AST) of enterococci, staphylococci and 
Escherichia coli. The results discussed in this report were obtained by National Reference 
Laboratories for Antimicrobial Resistance (NRL-AR) in Member States (MS) and in affiliated non-
Member States of the European Union. 
 
This is the 10th EQAS organized by the National Food Institute at the Technical University of 
Denmark (DTU Food) since its appointment as European Union Reference Laboratory for 
Antimicrobial Resistance (EURL-AR) by the European Commission (EC) in 2006. The EURL-AR 
is accredited by DANAK as provider of proficiency testing (accreditation no. 516); working with 
zoonotic pathogens and indicator organisms as bacterial isolates (identification, serotyping and 
antimicrobial susceptibility testing). 
 
This EQAS aims to: i) monitor the quality of AST results produced by NRL-AR, ii) identify 
laboratories which may need assistance to improve their performance in AST, and iii) determine 
possible topics for further research or elaboration. 
In reading this report, the following important considerations should be taken into account: 
- Expected results were generated by performing Minimum Inhibitory Concentration (MIC) 
determinations for all test strains in two different occasions at DTU-FOOD. These results were 
then verified by the United States Food and Drug Administration (FDA), Centre for Veterinary 
Medicine. Finally, a fourth MIC determination was performed at DTU-FOOD after preparation 
of the agar stab culture for shipment to participants to confirm that the vials contained the correct 
strains with the expected MIC values. 
 
- Evaluation is based on interpretations of AST values determined by the participants.
 
 This is in 
agreement with the method used by MS to report AST data to EFSA, and complies with “the 
main objective of this EQAS to assess and improve the comparability of surveillance and 
antimicrobial susceptibility data reported to EFSA by the different NRLs”, as stated in the 
protocol. 
- Evaluation of a result as “deviating from the expected interpretation” should be carefully 
analyzed in a self-evaluation procedure performed by the participant. Since methods used for 
MIC determination have limitations, it is not considered a mistake to obtain a one-fold dilution 
difference in the MIC of a specific antimicrobial when testing the same strains.  However, if the 
expected MIC is close to the breakpoint value for categorizing the strain as susceptible or 
resistant, a one-fold dilution difference, which is acceptable, may result in two different 
interpretations, i.e. the same strain will be categorized as susceptible and resistant, which will be 
evaluated as correct in one case and incorrect in the other if the evaluation is based on 
interpretation of MIC values. Since this report evaluates the interpretations of AST values, some 
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participants may find their results classified as wrong even though the actual MIC they reported 
is only one-fold dilution different from the expected MIC. In these cases, the participants should 
be confident about the good quality of their performance of AST. In the organization of the 
EQAS we try to avoid these situations by choosing test strains with MIC values distant from the 
breakpoints for resistance, which is not always feasible for all strains and all antimicrobials. 
Therefore, the EURL-AR network unanimously established that if there are less than 75 % 
correct results for a specific strain/antimicrobial combination, the reasons for this situation must 
be further examined and, on selected occasions explained in details case by case, these results 
may subsequently be  subtracted from the evaluation report. 
 
- The EURL-AR network agreed on setting the accepted deviation level for laboratory 
performance to 5 %. 
 
This report is approved in its final version by a technical advisory group composed by competent 
representatives from all NRLs who meet once a year at the EURL-AR workshop. 
All conclusions presented in this report are publicly available. However, participating laboratories 
are identified by codes and each code is known only by the corresponding laboratory. The full list of 
laboratory codes is confidential information known only by relevant representatives of the EURL-
AR and the EU Commission.  
2. Materials and Methods  
 
2.1 Participants in EQAS 2011 
In May 2011, a pre-notification to announce the EQAS 2011 on antimicrobial susceptibility testing 
of enterococci, staphylococci and E. coli was sent by e-mail to the 32 European NRLs for 
antimicrobial resistance designated by the MS (App. 1). Eight additional laboratories (one from 
each of the following countries: Denmark, Iceland, Norway, Romania, Serbia, Spain, Switzerland 
and The Netherlands) were invited to take part in the EQAS 2011 on the basis of their participation 
in previous EQAS iterations and/or affiliation to the EU. Participants represented all EU countries 
except Luxembourg (App. 2). One of the three NRLs from Spain declined to participate, therefore 
only 31 out of 32 NRL-AR submitted results (Figure 1). Among the designated NRLs, 24 submitted 
results for the enterococci strains and 29 submitted results for the staphylococci and the E. coli 
strains. The level of participation was similar to EQAS 2010 in which 22, 28 and 29 laboratories 
submitted results for enterococci, staphylococci and E. coli, respectively. In addition, this report 
includes results from one laboratory for each of the following EU-affiliated country non-MS: 
Norway, Serbia and Switzerland (Figure 1). 
To summarize, this report includes AST results of enterococci strains submitted by 27 laboratories, 
and AST results of staphylococci and E. coli strains submitted by 32 laboratories. 
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2.2 Strains  
Bacterial strains included in this EQAS (eight enterococci, eight staphylococci and eight E. coli) 
were selected among the DTU Food strain collection on the basis of antimicrobial resistance 
profiles and MIC values. For quality assurance purposes, one strain per each bacterial species tested 
has been included in all EQAS iterations performed to date, which represents an internal control. 
 
Figure 1. European map showing the countries participating in EQAS 2011 
 
 
Antimicrobial susceptibility testing of the EQAS strains was performed at DTU Food by MIC 
determination using the Sensititre system from Trek Diagnostic Systems. The MIC values obtained 
(App. 3) were used as reference values for this EQAS trial after verification performed by the U.S. 
FDA. Upon agreement between DTU Food and FDA obtained MIC values, the strains were 
inoculated in agar as stab cultures and dispatched to the participating laboratories. 
Reference strains E. faecalis ATCC 29212, S. aureus ATCC 25923, S. aureus ATCC 29213 and E. 
coli ATCC 25922 were given to new participating laboratories with instructions to save and 
maintain them for quality assurance purposes and future EQAS trials. 
      Participants in 
EQAS 2011 
      EU countries not 
participating 
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2.3 Antimicrobials  
The panels of antimicrobials recommended for AST are listed in Table 1. 
 
Table 1. Panel of antimicrobials recommended for susceptibility testing of bacteria included in this 
EQAS 2011 component 
Enterococci trial Staphylococci trial* Escherichia coli trial 
Ampicillin† Cefoxitin Ampicillin† 
Chloramphenicol† Chloramphenicol  Cefotaxime† 
Ciprofloxacin  Ciprofloxacin Cefoxitin 
Erythromycin† Erythromycin Ceftazidime 
Gentamicin† Florfenicol Ceftiofur 
Linezolid† Gentamicin Chloramphenicol† 
Streptomycin† Penicillin Ciprofloxacin† 
Quinupristin-dalfopristin† Streptomycin Florfenicol 
Tetracycline† Sulphonamides Gentamicin† 
Vancomycin† Tetracycline Nalidixic acid† 
 Trimethoprim Streptomycin† 
  Sulphonamides† 
  Tetracycline† 
  Trimethoprim† 
†Antimicrobials recommended by EFSA for monitoring antimicrobial resistance in Europe  
*No specific recommendations have been suggested by EFSA for monitoring resistance in staphylococci 
 
Guidelines for performing AST were set according to the Clinical and Laboratory Standards 
Institute (CLSI) document – M7-A8 (2009) “Methods for Dilution Antimicrobial Susceptibility 
Tests for Bacteria That Grow Aerobically; Approved Standard - Eighth Edition”. 
MIC results were interpreted by using EUCAST epidemiological cut-off values (www.eucast.org), 
as recommended by EFSA and described in the protocol (App. 4). Results of ESBL detection tests 
were interpreted according to the recommendations reported in the EUCAST expert rules.  
All the above-mentioned choices were made on the basis of agreements reached by NRL 
participants at EURL-AR workshops in previous years. 
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2.4 Distribution  
Protocols and all relevant information were uploaded on the EURL-AR website (http://www.eurl-
ar.eu), thereby EQAS participants could access necessary information at any time. In June 2011, 
bacterial strains in agar stab cultures were dispatched in double pack containers (class UN 6.2) to 
the participating laboratories according to the International Air Transport Association (IATA) 
regulations as UN3373, biological substances category B. 
 
2.5 Procedure  
Participants were instructed to keep the agar stab cultures refrigerated until performance of 
antimicrobial susceptibility tests (App. 4). In addition, instructions for interpretation of 
antimicrobial susceptibility test results were provided. For interpretation of MIC determination 
results, cut-off values were reported in the protocol (App. 4: Tables 1, 2 and 3). For interpretation of 
disk-diffusion (DD) method results, participants were advised to use interpretive breakpoints as in 
their routine methods (App. 5). In both cases, the EQAS test strains should have been categorized as 
resistant or susceptible, and the EURL-AR recommended interpreting intermediate results as 
susceptible. 
 
Of note, the terms ‘susceptible’, ‘intermediate’ and ‘resistant’ should be reserved to categorize 
strains in relation to the therapeutic application of antimicrobial agents, while interpretation of AST 
results based on epidemiological cut-off values should result in categorization of bacterial strains in 
‘wild-type’ or ‘non-wild-type’. However, due to different AST methods used by the participants and 
to simplify the interpretation of results, we will use the terms susceptible and resistant throughout 
this report even in the cases in which we refer to wild-type and non-wild-type strains.  
 
All participating laboratories were invited to enter the obtained results into an electronic record 
sheet at the EURL-AR web-based database through a secured individual login and password. 
Alternatively, it was offered the possibility to fill-in a record sheet (provided with the protocol) and 
send it to the EURL-AR by fax, mail or email. 
The record sheet contained also fields for reporting the results (zone diameters in millimeters or 
MIC values in μg/ml) obtained for the reference strains. These results were compared to the quality 
control ranges reported by CLSI in documents M31-A3 (2008) / M100-S21 (2011) (App. 6).  
The website was accessible for data entry until 9th September 2011. 
 
After the deadline for submission of results to the secured website, the participants were invited to 
login again to retrieve a database-generated individual report which contained an evaluation of the 
submitted results including possible deviations from the expected interpretations. Finally, 
participants were encouraged to complete an evaluation form available at the EURL-AR database 
with the aim to improve future EQAS trials 
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3. Results 
 
3.1 EQAS 2011 compared to previous EQAS iterations 
In EQAS 2011, the overall percentages of deviations from expected results were 5.04 %, 1.74 % 
and 2.65 % for enterococci, staphylococci and E. coli, respectively (Figure 2). These percentages 
are slightly higher compared to the ones observed in 2010. The internal control strains followed the 
same pattern and 5.04 %, 2.61 % and 2.73 % results deviating from the expected values were 
obtained for ENT-5.3, ST-5.1 and EC-5.5, respectively (Figure 2). Of note, these percentages do not 
include specific combinations strain/antimicrobial for which we observed less than 75 % reported 
results in agreement with the expected results (detailed explanation is provided in the paragraphs 
below).  
 
Figure 2. Overview of the percentages of deviations from expected results obtained in different 
EQAS iterations for the three bacterial species tested. The internal control strain is represented by a 
line. 
 
 
3.2 Deviations from expected results divided by species tested and AST method used 
In the data analysis, results were grouped according to the methods used by the participants as 
follows. The agar diffusion method and MIC determination were evaluated together as they are both 
quantitative methods giving results corresponding to the minimum concentration of an 
antimicrobial which inhibits growth of the bacterial strain tested. The ROSCO and DD methods 
were evaluated together since they are based on the same principle of antimicrobial diffusion in the 
agar. 
 
The highest percentage of results deviating from the expected values was obtained for the 
enterococci strains for which we observed 5 % of the overall results different from the expected 
                                                            
 
9 
interpretations (Figure 3). Higher percentages of deviations from expected results were obtained by 
performing AST by disk diffusion methods than MIC determinations (Figure 3), which is similar to 
the pattern observed in previous EQAS iterations. Indeed, the percentage of deviations from 
expected results was 10 times higher for results obtained by DD compared to MIC in the 
enterococci and E. coli trial. 
 
In EQAS 2011, 23, 25 and 27 participants performed AST by MIC determination for enterococci, 
staphylococci and E. coli, respectively, and four, seven and five participants performed AST by DD 
for enterococci, staphylococci and E. coli, respectively. 
 
Overall, the percentage of results in agreement with the expected values ranged from a minimum of 
92.1 % (strain ENT-5.7) to a maximum of 99.4 % (strains ST 5.5 and ST-5.7), as shown in Table 2. 
The staphylococci trial resulted in the highest percentages of results in agreement with the expected 
values. 
 
Detailed analysis of the results obtained for each species and strain tested in EQAS 2011 are 
reported in the following paragraphs. 
 
Figure 3. EQAS 2011: results deviating from the expected interpretation subdivided by tested 
species and antimicrobial susceptibility test method used 
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Table 2. Total number of antimicrobial susceptibility tests (AST) performed for each EQAS 2011 
strain and percentage (%) of correct results 
 
Strain* No. AST  
% 
correct  Strain* 
No. 
AST  
% 
correct  Strain* 
No. 
AST  
% 
correct  
ENT-5.1 230 96.1 ST-5.1 269 97.7  EC-5.1 372 96.2 
ENT-5.2 240 94.2 ST-5.2 327 96.0  EC-5.2 372 98.9 
ENT-5.3 238 95.0 ST-5.3 328 97.9  EC-5.3 372 98.9 
ENT-5.4 240 94.2 ST-5.4 327 99.1  EC-5.4 372 96.8 
ENT-5.5 229 96.5 ST-5.5 328 99.4  EC-5.5 371 97.0 
ENT-5.6 237 92.9 ST-5.6 326 98.8  EC-5.6 372 95.7 
ENT-5.7 228 92.1 ST-5.7 327 99.4  EC-5.7 372 98.7 
ENT-5.8 228 95.2 ST-5.8 329 98.8  EC-5.8 359 94.4 
*ENT, enterococci; ST, staphylococci; EC, Escherichia coli. 
 
As mentioned in the introduction, the EURL-AR network established that data should be 
individually examined and possibly subtracted from the general analysis if there are less than 75 % 
correct results for a strain/antimicrobial combination. 
3.2.1 Enterococci trial 
 
For ENT-5.2/Erythromycin, only 54 % of the results were in agreement with the expected 
interpretations and therefore the results were further examined. The distribution of MIC values 
obtained by participants performing MIC determination is reported in Figure 4. The expected MIC 
was 4 μg/ml, which results in categorization of the strain as susceptible. However, this value 
corresponds to the breakpoint for resistance (please refer to protocol, App. 4) and participants 
obtaining an MIC of 8 μg/ml, which is acceptable as it is within one-fold dilution difference from 
the expected value, categorized the strain as resistant and this was evaluated as an error. Ten 
participants obtained an MIC of 4 μg/ml and 6 participants obtained an MIC of 8 μg/ml (Figure 4). 
Among the four participants performing disk diffusion, three erroneously categorized the strain as 
resistant. All these results have been subtracted from the main analysis reported in this evaluation 
report since they cannot be representative of the quality of performance of the different participants 
in AST. 
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Figure 4. Distribution of MIC values obtained by participants performing MIC determination for 
the combination ENT-5.2/Erythromycin 
 
 
 
 
 
Similarly, results for ENT-5,6/Quinupristin-dalfopristin were subtracted from the main analysis 
reported in this evaluation report. In this case, 62 % of the participants categorized the strain as 
resistant which is in agreement with the expected result. The distribution of MIC values obtained by 
participants performing MIC determination is reported in Figure 5. The expected MIC was 8 μg/ml 
which corresponds to a categorization of the strain as resistant. Participants obtaining an MIC of 
4μg/ml reported the strain as susceptible according to the protocol, with one exception (Figure 5). 
However, performance of these participants is acceptable as the reported value is within one-fold 
dilution difference from the expected value. Two participants tested ENT-5.6/Quinupristin-
dalfopristin by disk diffusion and correctly categorized the strain as resistant. 
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Figure 5. Distribution of MIC values obtained by participants performing MIC determination for 
the combination ENT-5.6/Quinupristin-dalfopristin 
 
 
 
 
Analysis of results deviating from expected interpretation subdivided by strain showed that 
percentage of deviations from expected results ranged from ≤ 3 % to 7 % (Figure 6). The highest 
percentage (7 %) of disagreement with expected results was obtained for ENT-5.6 and ENT-5.7 
(Figure 6). Percentage of disagreement with expected results was ≤ 3 % for ENT-5.1 and ENT-5.5 
(Figure 6). Laboratories performing AST by disk diffusion reported results deviating from the 
expected categories in very high percentages ranging from 11 % (for ENT-5.1) to 29 % (for ENT-
5.7), as shown in Figure 6. Out of 27 laboratories participating in the enterococci trial, four 
performed AST by disk diffusion. 
 
Analysis of the results according to the tested antimicrobials showed that the highest percentages of 
deviation from expected interpretations were obtained in testing susceptibility to ampicillin (6 %), 
ciprofloxacin (8 %), gentamicin (8 %) and streptomycin (7 %) (Figure 7). Of note, ampicillin, 
gentamicin and streptomycin are among the EFSA-recommended antimicrobials (Table 1). 
Linezolid susceptibility tests resulted in 4 % of results in disagreement with expected values and 
tests of susceptibility to the remaining antimicrobials resulted in less than 3 % results deviating 
from the expected (Figure 7). 
An overview of obtained and expected results is reported in Appendix 7a. 
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Figure 6. Enterococci trial: results deviating from the expected interpretation subdivided by tested 
strain and antimicrobial susceptibility test method used 
 
 
Figure 7. Enterococci trial: results deviating from expected interpretation according to the tested 
antimicrobial 
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Analysis of the different strain/antimicrobial combinations showed that ST-5.1/Ciprofloxacin was 
categorized in agreement with the expected category by only 34 % of the participants. According to 
the decision established by the EURL-AR network, further analysis was performed to examine the 
reason of this unsatisfactory result. The distribution of MIC values obtained by participants 
performing MIC determination is reported in Figure 8. The expected MIC was 2 μg/ml, which 
results in categorization of the strain as resistant. However, this value is one-step dilution above of 
the cut-off value (please refer to protocol, App. 4) and participants obtaining an MIC of 1 μg/ml, 
which is acceptable as it is within one-fold dilution difference from the expected value, categorized 
the strain as susceptible and this was evaluated as an error. Thirteen participants obtained an MIC of 
1 μg/ml and 9 participants obtained an MIC of 2 μg/ml (Figure 8). Among the six participants 
performing disk diffusion, five erroneously categorized the strain as susceptible. All these results 
have been subtracted from the main analysis reported in this evaluation report since they cannot be 
representative of the quality of performance of the different participants in AST. 
3.2.2 Staphylococci trial 
 
Figure 8. Distribution of MIC values obtained by participants performing MIC determination for 
the combination ST-5.1/Ciprofloxacin 
 
 
 
Analysis of results deviating from expected interpretation subdivided by strain showed that 
percentage of deviations from expected results ranged from ≤ 1 % to 4 % (Figure 9). The highest 
percentage (4 %) of disagreement with expected results was obtained for ST-5.2 (Figure 9). 
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shown in Figure 9. Out of 32 laboratories participating in the staphylococci trial, seven performed 
AST by disk diffusion. 
 
Figure 9. Staphylococci trial: results deviating from the expected interpretation subdivided by 
tested strain and antimicrobial susceptibility test method used 
 
 
 
Analysis of the results according to the tested antimicrobials showed that the highest percentages of 
deviation from expected interpretations were obtained in testing susceptibility to sulphonamides (8 
%) (Figure 10). Trimethoprim and tetracycline susceptibility testing resulted in deviations from 
expected results between 2 % and 3 %, while tests of susceptibility to the remaining antimicrobials 
resulted in less than 2 % results deviating from the expected (Figure 10). 
An overview of obtained and expected results is reported in Appendix 7b. 
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Figure 10. Staphylococci trial: results deviating from expected interpretation according to the tested 
antimicrobial 
 
 
 
Analysis of the different strain/antimicrobial combinations showed that EC-5.4/Ceftazidime was 
categorized in agreement with the expected category by only 38 % of the participants. According to 
the decision established by the EURL-AR network, further analysis was performed to examine the 
reason of this unsatisfactory result. The distribution of MIC values obtained by participants 
performing MIC determination is reported in Figure 11. The expected MIC was 1 μg/ml, which 
results in categorization of the strain as resistant. However, this value is one-step dilution above of 
the cut-off value (please refer to protocol, App. 4) and participants obtaining an MIC of 0.5 μg/ml, 
which is acceptable as it is within one-fold dilution difference from the expected value, categorized 
the strain as susceptible and this was evaluated as an error. Thirteen participants obtained an MIC of 
1 μg/ml and six participants obtained an MIC of 2 μg/ml (Figure 11). It should be stressed, however, 
that the phenotype of this isolate as regards ceftazidime is very specific due to the blaCTX-M-15-gene. 
The isolate exhibits resistance (borderline) to this drug, but does not exhibit synergy when testing 
the combination of ceftazidime/clavulanic acid compared to ceftazidime. All the five participants 
performing disk diffusion erroneously categorized the strain as susceptible. All these results have 
been subtracted from the main analysis reported in this evaluation report since they cannot be 
representative of the quality of performance of the different participants in AST. 
3.2.3 Escherichia coli trial 
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Figure 11. Distribution of MIC values obtained by participants performing MIC determination for 
the combination EC-5.4/Ceftazidime 
 
 
 
 
As EC-5.8/Trimethoprim was categorized in agreement with the expected category by only 71 % of 
the participants, further analysis was performed to examine the reason of this unsatisfactory result. 
The distribution of MIC values obtained by participants performing MIC determination is reported 
in Figure 12. The expected MIC was ≤ 1 μg/ml, which results in categorization of the strain as 
susceptible. The cut-off value for categorizing E. coli as resistant to trimethoprim is > 2 μg/ml. Five 
and 12 participants determined an MIC ≤ 1 μg/ml and  =  2 μg/ml, respectively, and correctly 
classified the strain as trimethoprim-susceptible (Figure 12). Six and two participants determined an 
MIC = 4 μg/ml and ≥ = 8 μg/ml, respectively, and categorized the strain as resistant (Figure 12). All 
the three participants performing disk diffusion correctly categorized the strain as susceptible. All 
these results have been included in this evaluation report since in this case evaluation based on MIC 
values and on interpretation of MIC values would lead to identical conclusions. 
 
Analysis of results deviating from expected interpretation subdivided by strain showed that 
percentage of deviations from expected results ranged from ≤ 1 % to 6 % (Figure 13). The highest 
percentage (6 %) of disagreement with expected results was obtained for EC-5.8 (Figure 13). 
Percentage of disagreement with expected results was ≤ 1 % for EC-5.2, EC-5.3 and EC-5.7 (Figure 
13). Laboratories performing AST by disk diffusion obtained results deviating from the expected 
categories in percentages higher than the ones obtained by MIC determination, as shown in Figure 
13. These differences varied from two to seven times higher percentages of deviations in AST 
performed by DD compared to MIC in strains EC-5.3 and EC-5.8, respectively (Figure 13). Out of 
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32 laboratories participating in the E. coli trial, five performed AST by disk diffusion. 
An overview of obtained and expected results is reported in Appendix 7c. 
 
Figure 12. Distribution of MIC values obtained by participants performing MIC determination for 
the combination EC-5.8/Trimethoprim 
 
 
 
Figure 13. Escherichia coli trial: results deviating from the expected interpretation subdivided by 
tested strain and antimicrobial susceptibility test method used 
Analysis of the results according to the tested antimicrobials showed that the highest percentages of 
deviation from expected interpretations were obtained in testing susceptibility to ceftazidime and 
 
0 
2 
4 
6 
8 
10 
12 
14 
1 2 4 8 >32 
N
um
be
r o
f l
ab
or
at
or
ie
s 
MIC values EC-5.8/Trimethoprim 
Categorized as susceptible Categorized as resistant 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
20 
EC-5.1 EC-5.2 EC-5.3 EC-5.4 EC-5.5 EC-5.6 EC-5.7 EC-5.8 
Pe
rc
en
ta
ge
 o
f d
ev
ia
tio
ns
 fr
om
 e
xp
ec
te
d 
re
su
lts
 
Escherichia coli strains EQAS 2011 
MIC 
DD 
TOTAL 
                                                            
 
19 
ciprofloxacin (ca. 7 %) (Figure 14). Nalidixic acid and trimethoprim susceptibility testing resulted 
in ca. 5 % and 3 % deviations from expected results, respectively, while tests of susceptibility to the 
remaining antimicrobials resulted in less than 2 % results deviating from the expected (Figure 14). 
No deviations were observed in ceftiofur susceptibility testing (Figure 14). 
An overview of obtained and expected results is reported in Appendix 7c. 
 
Figure 14. Escherichia coli trial: results deviating from expected interpretation according to the 
tested antimicrobial 
 
 
*Antimicrobials recommended by EFSA for antimicrobial resistance monitoring within EU 
 
As described in the protocol, MIC values and related interpretations for cefotaxime, ceftazidime and 
ceftiofur should be reported as found according to EUCAST expert rules. Ceftiofur susceptibility 
testing was performed 100 % correctly by the participants who tested this antimicrobial, while up to 
7 % of results for ceftazidime susceptibility testing were in disagreement with the expected values. 
Beta-lactamase-producing E. coli 
 
Confirmation of beta-lactamase production is a mandatory component of this EQAS. All E. coli 
strains resistant to cefotaxime, ceftazidime and/or ceftiofur should undergo confirmatory tests for 
beta-lactamase production. Participant # 54 did not perform this component. 
EC-5.4 and EC-5.5 were extended-spectrum beta-lactamase (ESBL) producers and EC-5.8 was an 
AmpC-producer. 
Deviations from expected results were obtained as follows. 
Participants # 22, # 46 and did not identify EC-5.4 as an ESBL producer as they did not obtained 
signs of synergy (please refer to protocol, App.4) by testing cefotaxime and cefotaxime+clavulanic 
acid. 
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Ten participants did not identify strain EC-5.8 as AmpC producer. Overall, these participants 
performed correct procedures except for the fact that they did not test for cefoxitin resistance 
despite having a strain resistant to cefotaxime, ceftazidime and/or ceftiofur and with no synergy by 
testing a cephalosporin in combination with clavulanic acid. One (# 41) of the participants not 
identifying EC-5.8 as AmpC producer classified instead the strain as ESBL producer since a 
phantom area was observed in the test with cefotaxime and cefotaxime+clavulanic acid. One 
participant (# 22) classified EC-5.8 as ESBL and AmpC-producer since an increase of the inhibition 
zone diameter ≥ 5 mm was observed by testing cefotaxime+clavulanic acid compared to cefotaxime 
alone. 
 
Finally, two participants (# 21 and # 22) erroneously classified strain EC-5.6 as ESBL producer. In 
this case, participant # 21 categorized the strain as cefotaxime and ceftazidime resistant, performed 
confirmatory test and found synergy by testing cefotaxime and cefotaxime+clavulanic acid. 
Participant # 22 performed confirmatory test despite having correctly categorized EC-5.6 as 
cefotaxime and ceftazidime susceptible and classified the strain as ESBL producer because there 
was an enhancement of activity of cefotaxime+clavulanic acid compared to cefotaxime alone that 
was interpreted as synergy effect. 
 
3.3 Deviations from expected results analyzed by participating laboratory 
Analysis of laboratory performance of AST restricted to EFSA-recommended antimicrobials 
showed that six out of 27 participants obtained a percentage of deviations from expected results 
higher than 5 % (Figure 15). Also by including all antimicrobials tested, six out of 27 participants 
obtained a percentage of deviations from expected results higher than 5 %, but one of these 
participants was actually below the 5 % threshold when considering EFSA-recommended 
antimicrobials only (Figure 15). All participants performing AST by disk diffusion obtained more 
than 5 % deviations from expected results (Figure 15). 
3.3.1 Enterococci trial 
Participant # 54 obtained deviations from expected results mainly in testing ampicillin (resistant 
strains classified as susceptible) and ciprofloxacin, gentamicin, linezolid and vancomycin 
(susceptible strains classified as resistant). Participant # 18 obtained deviations from expected 
results mainly in testing gentamicin and streptomycin (susceptible strains classified as resistant). 
Participant # 41 obtained deviations from expected results mainly in testing ciprofloxacin 
(susceptible strains classified as resistant). In the remaining cases, deviations from expected results 
were observed for different antimicrobials and were represented both by classification of 
susceptible strains as resistant and vice versa (App. 8a). 
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Figure 15. Percentage of deviations from expected results obtained by each laboratory in the 
enterococci trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing including EFSA-recommended 
antimicrobials only 
 
*Laboratories performing AST by disc diffusion 
 
In summary, 21 of 27 participants in the enterococci trial achieved the acceptance level by having 
less than 5 % of results deviating from the expected values (Figure 16). Among the six participants 
who did not meet the acceptance level, one was considered an outlier (#54) (Figure 16). 
Deviations from expected results obtained by each participant in the enterococci trial are reported in 
Appendix 8a. 
 
Figure 16. Number of laboratories categorized according to the percentage of deviations from 
expected results obtained by testing enterococci strains for susceptibility to EFSA-recommended 
antimicrobials 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
54
* 
18
* 6 
40
* 41
 
26
* 46
 
19
 
29
 
42
 
39
 2 37
 
11
 1 20
 
34
 9 12
 
15
 
16
 
17
 
22
 
23
 
25
 
33
 
36
 
Pe
rc
en
ta
ge
 o
f d
ev
ia
tio
ns
 fr
om
 
ex
pe
ct
ed
 re
su
lts
 
Laboratory ID number 
EFSA antimicrobials All antimicrobials 
0 
2 
4 
6 
8 
10 
12 
0-1 >1-3 >3-5 >5-7 >15-20 >25 
N
um
be
r o
f l
ab
or
at
or
ie
s 
Percentage of deviations from expected results 
Acceptance limit 
Change in scale 
                                                            
 
22 
Analysis of laboratory performance of AST showed that four out of 32 participants obtained a 
percentage of deviations from expected results higher than 5 % (Figure 17). One out of seven 
participants performing AST by disk diffusion obtained more than 5 % deviations from expected 
results (Figure 17). 
3.3.2 Staphylococci trial 
Participant # 6 obtained deviations from expected results mainly in testing sulphonamides 
(susceptible strains classified as resistant). Participant # 40 obtained deviations from expected 
results mainly in testing tetracycline (resistant strains classified as susceptible). Participant # 41 
obtained deviations from expected results mainly in testing sulphonamides, tetracycline and 
trimethoprim (susceptible strains classified as resistant). Participant # 18 obtained deviations from 
expected results for different antimicrobials and both classification of susceptible strains as resistant 
and vice versa were observed (App. 8b). 
 
Figure 17. Percentage of deviations from expected results obtained by each laboratory in the 
staphylococci trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing  
 
 
*Laboratories performing AST by disc diffusion 
 
In summary, 28 of 32 participants in the staphylococci trial achieved the acceptance level by having 
less than 5 % of results deviating from the expected values (Figure 18). No outlier was identified 
among the four participants who did not meet the acceptance level (Figure 18). However, the 
participant (# 41) who did not report any information concerning methicillin resistance have been 
contacted by the EURL-AR to agree on possible supportive actions. 
Deviations from expected results obtained by each participant in the staphylococci trial are reported 
in Appendix 8b. 
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Figure 18. Number of laboratories categorized according to the percentage of deviations from 
expected results obtained by testing staphylococci strains for antimicrobial susceptibility 
 
 
 
Analysis of laboratory performance of AST restricted to EFSA-recommended antimicrobials 
showed that seven out of 32 participants obtained a percentage of deviations from expected results 
higher than 5 % (Figure 19). By including all antimicrobials tested, six out of 32 participants 
obtained a percentage of deviations from expected results higher than 5 % (Figure 19). Four out of 
five participants performing AST by disk diffusion obtained more than 5 % deviations from 
expected results (Figure 19). 
3.3.3 Escherichia coli trial 
Participant # 54 obtained deviations from expected results mainly in testing ceftazidime and 
ciprofloxacin (resistant strains classified as susceptible) and gentamicin (resistant strains classified 
as susceptible and vice versa). Participant # 21 obtained deviations from expected results for 
different antimicrobials including cefotaxime, ceftazidime, nalidixic acid and ciprofloxacin 
(susceptible strains classified as resistant). Participant # 40 obtained deviations from expected 
results for different antimicrobials including cefotaxime, ceftazidime, gentamicin and tetracycline 
(resistant strains classified as susceptible), and ciprofloxacin (resistant strains classified as 
susceptible and vice versa). Participants # 14 and 15 obtained deviations from expected results for 
different antimicrobials including cefotaxime and ceftazidime (resistant strains classified as 
susceptible), and nalidixic acid (resistant strains classified as susceptible). Participants # 19 
obtained deviations from expected results mainly in testing ciprofloxacin (resistant strains classified 
as susceptible). In the remaining case, deviations from expected results were observed for different 
antimicrobials and were represented both by classification of susceptible strains as resistant and 
viceversa (App. 8c). 
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Figure 19. Percentage of deviations from expected results obtained by each laboratory in the 
Escherichia coli trial. The laboratories were ranked by decreasing percentage of deviations from 
expected results in antimicrobial susceptibility testing  
 
 
*Laboratories performing AST by disc diffusion 
 
In summary, 25 of 32 participants in the E. coli trial achieved the acceptance level by having less 
than 5 % of results deviating from the expected values (Figure 20). Among the seven participants 
who did not meet the acceptance level, one was considered an outlier (Figure 20). 
Deviations from expected results obtained by each participant in the E. coli trial are reported in 
Appendix 8c. 
 
Figure 20. Number of laboratories categorized according to the percentage of deviations from 
expected results obtained by testing Escherichia coli strains for susceptibility to EFSA-
recommended antimicrobials 
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3.4 Deviations from expected results for the reference strains 
The results for antimicrobial susceptibility testing of the reference strains have been evaluated 
according to the CLSI-established quality control (QC) ranges (App. 6). 
 
Twenty-one participants performed AST of E. faecalis ATCC 29212 by MIC determination. One 
result out of the QC range was obtained for ampicillin susceptibility tests (Table 3). Two results out 
of the QC range were obtained for erythromycin and for tetracycline susceptibility tests (Table 3). 
In summary, out of 187 tests performed overall, 181 were correct. 
3.4.1 Enterococcus faecalis ATCC 29212 
 
Table 3. Antimicrobial susceptibility testing of Enterococcus faecalis ATCC 29212 by MIC 
determination: deviations from expected values and minimum and maximum values reported for 
each tested antimicrobial  
Enterococcus faecalis ATCC 29212 
Antimicrobial QC range (MIC) 
Min. 
value 
Max. 
value 
No. of deviations 
from expected result/ 
Total no. of tests 
Ampicillin  0.5 - 2 1 4 1/19 
Chloramphenicol 1 - 4 4 8 0/20 
Ciprofloxacin  0.25 - 2 0.5 1 0/16 
Erythromycin 1 - 4 0.25 4 2/21 
Gentamicin 4 - 16 4 ≤ 128 0/21 
Linezolid 1 - 4 1 2 0/18 
Quinu-dalfo-pristin  2 - 8 2 8 0/10 
Streptomycin  n.a.* 32 512 0/20 
Tetracycline 8 - 32 4 32 2/21 
Vancomycin 1 - 4 1 4 0/21 
*n.a., not applicable 
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Five participants performed AST of S. aureus ATCC 25923 by disk diffusion. One result out of the 
QC range was obtained for cefoxitin, chloramphenicol and gentamicin susceptibility tests (Table 4). 
Two results out of the QC range were obtained for penicillin susceptibility tests (Table 4). In 
summary, out of 40 tests performed overall, 35 were correct. 
3.4.2a Staphylococcus aureus ATCC 25923 
One participant performed AST of S. aureus ATCC 25923 by ROSCO method, and the results were 
not included in Table 4 because the quality control values were different from the ones used for disk 
diffusion. This participant obtained a result out of the QC range for erythromycin and gentamicin 
(obtained zone diameter smaller than the lowest acceptable value in the QC range). 
 
Table 4. Antimicrobial susceptibility testing of Staphylococcus aureus ATCC 25923 by disk 
diffusion: deviations from expected values and minimum and maximum values reported for each 
tested antimicrobial  
 
Staphylococcus aureus ATCC 25923 
Antimicrobial 
QC 
range 
(MIC) 
Min. 
value 
Max. 
value 
No. of deviations from 
expected result/Total 
no. of tests 
Cefoxitin 23 - 29 26 33 1/6 
Chloramphenicol 16 - 26 21 27 1/4 
Ciprofloxacin 22 - 30 22 30 0/4 
Erythromycin 22 - 30 23 30 0/5 
Florfenicol n. a. 22 27 n. a. 
Gentamicin 19 - 27 19 28 1/5 
Penicillin 26 - 37 32 40 2/5 
Streptomycin 14 - 22 15 19 0/3 
Sulfisoxazole 24 - 30 24 29 0/3 
Tetracycline 24 - 34 28 32 0/4 
Trimethoprim 19 - 26 20 24 0/2 
      
  
                                                            
 
27 
Twenty-four participants performed AST of S. aureus ATCC 25913 by MIC determination (Table 
5). Out of 204 tests performed overall, 203 were correct. 
3.4.2b Staphylococcus aureus ATCC 25913 
 
Table 5. Antimicrobial susceptibility testing of Staphylococcus aureus ATCC 25913 by MIC 
determination: deviations from expected values and minimum and maximum values reported for 
each tested antimicrobial  
 
     Staphylococcus aureus ATCC 25913 
Antimicrobial 
QC 
range 
(MIC) 
Min. 
value 
Max. 
value 
No. of deviations from 
expected result/Total 
no. of tests 
Cefoxitin 1 - 4 1 4 0/19 
Chloramphenicol 2 - 8 2 8 0/23 
Ciprofloxacin 0.12 - 0.5 0.25 0.5 0/23 
Erythromycin 0.25 - 1 0.25 1 0/24 
Florfenicol 2 - 8 4 8 0/9 
Gentamicin 0.125 - 1 0.25 
≤ 2 0/23 
Penicillin 0.25 - 2 0.12 2 1/24 
Sulfisoxazole 32 - 128 64 128 0/12 
Tetracycline 0.125 - 
1 0.25 1 0/24 
Trimethoprim 1 - 4 1 4 0/23 
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Four participants performed AST of E. coli ATCC 25922 by disk diffusion. One result out of the QC 
range was obtained for tetracycline susceptibility tests (Table 6). In summary, out of 42 tests 
performed overall, 41 were correct. 
3.4.3 Escherichia coli ATCC 25922 
 
Table 6. Antimicrobial susceptibility testing of Escherichia coli ATCC 25922 by disk diffusion: 
deviations from expected values and minimum and maximum values reported for each tested 
antimicrobial  
 
Escherichia coli ATCC 25922 
Antimicrobial 
QC 
range 
(MIC) 
Min. 
value 
Max. 
value 
No. of deviations from 
expected result/Total 
no. of tests 
Ampicillin 16 - 22 19 20 0/2 
Cefotaxime 29 - 35 30 35 0/4 
Cefoxitin 23 - 29 26 28 0/4 
Ceftazidime 25 - 32 26 32 0/3 
Ceftiofur  26 - 31 26 29 0/3 
Chloramphenicol 21 - 27 22 26 0/3 
Ciprofloxacin 30 - 40 35 38 0/3 
Gentamicin 19 - 26 20 26 0/4 
Imipenem 26 - 32 30 30 0/1 
Nalidixic acid 22 - 28 25 26 0/4 
Streptomycin 12 - 20 16 18 0/2 
Sulfisoxazole 15 - 23 21 23 0/2 
Tetracycline 18 - 25 24 27 1/4 
Trimethoprim 21 - 28 26 28 0/3 
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Twenty-six participants performed AST of E. coli ATCC 25922 by MIC determination. One result 
out of the QC range was obtained for ceftazidime susceptibility tests (Table 7). Two results out of 
the QC range were obtained for gentamicin and for sulfisoxazole susceptibility tests, and three 
results out of the QC range were obtained for ciprofloxacin susceptibility tests (Table 7). In 
summary, out of 287 tests performed overall, 279 were correct. 
 
Table 7. Antimicrobial susceptibility testing of Escherichia coli ATCC 25922 by MIC 
determination: deviations from expected values and minimum and maximum values reported for 
each tested antimicrobial 
     Escherichia coli ATCC 25922 
Antimicrobial QC range (MIC) 
Min. 
value 
Max. 
value 
No. of deviations from 
expected result/Total no. of 
tests 
Ampicillin 2 - 8 2 8 0/26 
Cefotaxime 0.03 - 0.125 0.06 0.125 0/26 
Cefoxitin 2 - 8 2 8 0/8 
Ceftazidime 0.06 - 0.5 0.25 1 1/23 
Ceftiofur  0.25 - 1 0.25 0.5 0/4 
Chloramphenicol 2 - 8 2 8 0/26 
Ciprofloxacin 0.004 - 0.016 0.008 0.06 3/26 
Gentamicin 0.25 - 1 0.25 2 2/26 
Imipenem 0.06 - 0.25 0.12 0.5 0/4 
Nalidixic acid 1 - 4 2 4 0/26 
Streptomycin 4 - 16 4 8 0/25 
Sulfisoxazole 8 - 32 8 128 2/17 
Tetracycline 0.5 - 2 1 2 0/25 
Trimethoprim 0.5 - 2 0.5 2 0/25 
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4. Discussion 
In the overall analysis of results, it could be observed that the levels of deviations from the expected 
results were low and comparable to last year for AST of staphylococci and E. coli, while there was 
an increase in deviations from the expected results for AST of enterococci (Figure 2). The 
percentage of deviations from the expected results for AST of the internal control strains followed 
the general trend observed in the overall EQAS 2011 (Figure 2). Of note, results for the S. aureus 
internal control strain were considerably improved compared to last year (Figure 2). 
4.1 General overview 
 
It is important to consider that the number of EQAS participants changes from year to year, which 
implies that comparisons among different EQAS iterations are difficult to interpret. Results from 
three laboratories from EU–affiliated countries non-MS were included in this report, which is a 
novelty compared to reports issued in previous years. Among the NRLs designated by the MS, one 
declined to participate in all the three components of this EQAS 2011, and never participated in any 
of the enterococci, staphylococci and E. coli EQAS conducted to date. 
 
The EURL-AR has emphasized the need for harmonization of AST methodology among NRLs, and 
has recommended MIC determination on several occasions. In this EQAS trial, the number of 
participants performing MIC determination is comparable to the high numbers observed last year. 
Of note, enterococci and E. coli AST performed by MIC determination resulted in significantly 
higher percentages of correct results compared to results obtained by DD over the different EQAS 
iterations. Therefore, the EURL-AR encourages participants using disk diffusion to test enterococci 
and E. coli to consider changing method and harmonizing with the majority of NRLs which perform 
MIC determination. 
 
The percentages of results deviating from the expected interpretations varied from 3 % to 7 % 
among the different test strains (Figure 6). These relatively high percentages of deviations from 
expected results were mainly generated by participants performing AST by disk diffusion (Figure 
6).  
4.2 Enterococci trial 
 
Similar problems were observed last year in EQAS 2010. Enterococci appear to be quite difficult to 
test correctly by disk diffusion, and several different reasons may be found. Unsatisfactory 
performance may be due to factors related to the strains as certain enterococci strains may require 
incubation times longer than overnight incubation. In addition, inoculum size and density may also 
represent a source of errors in AST performance. 
Outcome of AST by disk diffusion is also influenced by factors related to the agar media like 
humidity, pH and volume. Finally, there may be factors related to the antimicrobial-containing disks 
like expiry date, humidity and concentration used.  
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Susceptibility tests to ampicillin, ciprofloxacin, gentamicin and streptomycin resulted in the highest 
percentages of results deviating from the expected interpretations (Figure 7). For ampicillin, 
ciprofloxacin and gentamicin, the incorrect classification was represented by susceptible strains 
reported as resistant, which was mainly obtained by participants # 54, # 41 and # 18 (App. 8a). For 
streptomycin, the incorrect classification was represented both by susceptible strains reported as 
resistant and vice versa, which was reported by various participants including # 54, # 46, # 18 and # 
6 (App. 8a). Of note, ampicillin, gentamicin and streptomycin are among the EFSA-recommended 
antimicrobials, which implies that it is important that each participant who submitted incorrect 
results takes corrective actions. 
 
The number of participants submitting more than 5 % results deviating from the expected 
interpretation was six, which is one more compared to last year. Of note, all the four participants 
testing enterococci by disk diffusion obtained percentages of results deviating from the expected 
interpretations above 5 %, which is considered the threshold for acceptable AST performance. 
Among the six participants who did not meet the 5 % acceptance threshold, one was considered an 
outlier with deviations mainly due to susceptible strains classified as resistant to ampicillin, 
ciprofloxacin, gentamicin, linezolid and vancomycin. Another participant reported 17 % of results 
in disagreement with the expected values. Both participants have been contacted by the EURL-AR 
to identify possible causes of this unsatisfactory performance and to improve the quality of results. 
 
The number of participants performing AST with 100 % agreement with the expected results was 
10 (37 %), which is three laboratories less than last year.  
 
AST of the quality control strain E. faecalis ATCC 29212 was quite satisfactory for the 21 
participants that tested this strain by MIC determination (Table 3). In summary, out of 187 tests 
performed overall, 181 (97 %) were correct. Of note, the outlier identified in the enterococci trial 
did not report any value for the quality control strain. 
 
The percentages of results deviating from the expected interpretations ranged from 1 % to 4 % 
among the different test strains (Figure 9). As observed last year, the percentages of deviations from 
expected results generated by participants performing MIC determination and by participants 
performing DD were not considerably different (Figure 9). The number of participants performing 
MIC determination increased from 21 (EQAS 2010) to 25 participants. 
4.3 Staphylococci trial 
The overall satisfactory results obtained in the staphylococci trial show a successful implementation 
of the new method for AST. 
 
Identification of methicillin-resistant strains was generally satisfactory, which demonstrated that 
laboratories within the EURL-AR network correctly identify MRSA. However, few improvements 
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are necessary as participant # 41 did not report results concerning methicillin resistance, and 
participant # 18 did not report any result for ST-5.5 (but correctly reported ST-5.1 and ST-5.8 as 
methicillin-resistant). Participant # 4 reported erroneously strain ST-5.8 as methicillin-susceptible. 
Of note, participant # 39 performed this test for the first time in this EQAS iteration and obtained 
100 % correct results. 
 
The number of participants submitting more than 5 % results deviating from the expected 
interpretation was four (Figure 10), which is two more compared to last year. No outliers were 
identified in the staphylococci trial. However, lab # 41 obtained 14 % results deviating from 
expected values, and the EURL-AR has contacted this participant to identify possible causes of this 
unsatisfactory performance and to improve the quality of results. 
 
The number of participants performing AST with 100 % agreement with the expected results was 
17 (53 %) and additional six (18 %) laboratories reported only 1 % of results deviating from 
expected values. 
 
AST of the quality control strain S. aureus ATCC 25923 (for DD) resulted in 88 % correct tests 
(Table 4), and AST of the quality control strain S. aureus ATCC 29213 (for MIC determination) 
resulted in 99 % correct tests (Table 5). Overall, this performance was quite satisfactory.  
 
The percentages of results deviating from the expected interpretations varied from 1 % to 6 % 
among the different test strains (Figure 13). These relatively high percentages of deviations from 
expected results were mainly generated by participants performing AST by disk diffusion (Figure 
13).  
4.4 Escherichia coli trial 
 
Susceptibility tests to ceftazidime and ciprofloxacin resulted in the highest percentages (ca. 7 %) of 
results deviating from the expected interpretations (Figure 14). For ceftazidime, the incorrect 
classification was represented by susceptible strains reported as resistant, which was reported by 
various participants including # 21, # 29, # 34 and # 39 (App. 8c). For ciprofloxacin, the incorrect 
classification was represented both by susceptible strains reported as resistant and vice versa, which 
was obtained by various participants including # 4, # 19, # 21 and # 42 (App. 8c). These results 
indicate that increased attention should be paid to correctly categorize strains according to 
susceptibility to critically important antimicrobials like ciprofloxacin (fluoroquinolone) and 
ceftazidime (cephalosporin). In addition, susceptibility tests to nalidixic acid and trimethoprim 
resulted in higher percentages of results deviating from the expected interpretations compared to 
last year (≤ 3 % in EQAS 2010; ca. 5 % in EQAS 2011. Figure 14). Of note, nalidixic acid, 
ciprofloxacin and trimethoprim are among the EFSA-recommended antimicrobials, which implies 
that it is important that each participant who submitted incorrect results takes corrective actions. 
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The number of participants submitting more than 5 % results deviating from the expected 
interpretation was seven, which is much higher than last year when only two participants performed 
outside the acceptance level. Four out of five participants testing E. coli by disk diffusion obtained 
percentages of results deviating from the expected interpretations above the 5 % threshold for 
acceptable AST performance. Among the seven participants who did not meet the 5 % acceptance 
threshold, one was considered an outlier. This participant reported wrong results mainly for 
ciprofloxacin and gentamicin by categorizing resistant strains as susceptible, and will be soon 
contacted by the EURL-AR to identify possible causes of this unsatisfactory performance and to 
improve the quality of results. 
 
The number of participants performing AST with 100 % agreement with the expected results was 
14 (44 %). 
 
Detection of beta-lactamases of the ESBL and AmpC-type should be further improved especially 
concerning identification of AmpC-type beta-lactamases. Participants did not show difficulties in 
correctly identifying cephalosporin resistance and a general improvement was observed compared 
to last year. However, there are limitations in the correct performance and interpretation of ESBL 
and AmpC confirmatory tests.  
 
AST of the quality control strain E. coli ATCC 25922 resulted in 98 % and 97 % correct tests by 
DD and MIC determination, respectively (Tables 6 and 7). Overall, this performance was quite 
satisfactory. However, the majority of deviations was observed for tests of ciprofloxacin and this 
results must be improved in future trials since ciprofloxacin is among the critically important 
antimicrobials as defined by the WHO. Interestingly, the participants mentioned above reporting 
more than 5 % incorrect results for specific antimicrobials (ceftazidime and ciprofloxacin) had no 
values outside the QC range, which may indicate that the erroneous results were accidentally 
produced and there should not be any major issue in the methodology used. In any case, these 
participants are invited to review the causes of incorrect results for the E. coli test strains and 
possibly perform the test again. Of note, the outlier identified in the E. coli trial did not report any 
value for the quality control strain. 
 
5. Conclusions 
The number of laboratories not performing AST within the acceptable level (i.e. > 5 % results 
deviating from the expected values) was relatively low, but higher compared to last year especially 
in the enterococci trial. One participant was classified as an outlier both in the enterococci and in 
the E. coli trial. Since one of the tasks of the EURL-AR is to give specific recommendations 
targeting individual difficulties in performing acceptable AST, laboratories considered outliers have 
been contacted to assess the causes of inadequate AST performance and provide guideline to 
improve the methods used. These individual contacts should be taken as an opportunity to improve 
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knowledge on AST. Notably, participant # 39, who received a short visit by representatives of the 
EURL-AR last year, performed MRSA and ESBL confirmatory tests for the first time in this EQAS 
iteration and obtained excellent results. 
 
Results obtained by MIC determination exhibited considerably higher level of agreement with the 
expected results compared to results obtained by disk diffusion both for the enterococci and the E. 
coli trials. As this situation was observed also in previous EQAS iterations, the EURL-AR strongly 
encourages participants to perform AST by MIC determination which seems to be more reliable and 
reproducible.  
 
Additional improvements are needed to correctly identify E. coli producing beta-lactamases of the 
ESBL and AmpC-type as this is a priority area within the EURL-AR activities. We strongly 
encourage participants having problems in identifying these strains to perform a re-test as a training 
exercise and to contact us in case any discussion is needed. 
 
Finally, the EURL-AR is open to suggestions to improve future EQAS trials and invites the entire 
network to contribute with ideas for training courses and specific focus areas to expand our 
knowledge in antimicrobial resistance. 
 Technical University of Denmark 
National Food Institute 
Kemitorvet 
Building 204 
DK-2800 Kgs. Lyngby 
Denmark 
Tel +45 35 88 70 00 
Dir. +45 35 88 62 84 
Fax +45 35 88 63 41  
vabo@food.dtu.dk
www.food.dtu.dk
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      Lyngby, 14 April 2011 
 
EURL‐AR EQAS 2011 FOR E. COLI, STAPHYLOCOCCI AND ENTEROCOCCI: 
PRE‐NOTIFICATION 
 
The EURL‐AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable 
laboratory results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Escherichia coli isolates, 
eight staphylococci and eight enterococci isolates. In addition, Quality Control (QC) strains E. 
coli ATCC 25922 (CCM 3954), Enterococcus faecalis ATCC 29212 (CCM 4224), Staphylococcus 
aureus ATCC 25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) 
(for MIC) will be distributed to new participating laboratories. 
This EQAS is specifically for NRLs on antimicrobial resistance. All laboratories receiving this 
pre‐notification are automatically regarded as participants and do not need to sign up to 
participate. Participation is free of charge for all EU designated NRLs.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “Biological Substance Category B”: eight E. coli, eight 
staphylococci, eight enterococci and, for new participants, the QC strains mentioned above. 
Please inform me about documents or other information that can simplify custom procedures 
(e.g., specific text that should be written on the accompanying letter). To avoid delays, I 
kindly ask you to send me this information already at this stage. 
TIMELINE FOR EQAS 2011: 
 Shipment of isolates and protocol. The isolates will be shipped in June 2011. The protocol 
for reviving the isolates and performing antimicrobial susceptibility tests will be available 
at www.eurl‐ar.eu 
 Submission of results. Results must be submitted to the National Food Institute no later 
than 9 September 2011 via the password‐protected website. Upon reaching the deadline, 
each participating laboratory is kindly asked to enter the password‐protected website 
once again to download an automatically generated evaluation report.  
 EQAS report. A report summarising and comparing results for all participants will be 
issued. A code which is known only to the National Food Institute and the EU Commission 
is assigned to participating laboratories, thus guaranteeing anonymity. 
 Next EQAS. The next EURL‐AR EQAS component will be the antimicrobial susceptibility 
testing of Salmonella and Campylobacter, and it will be carried out in October 2011. 
 
Please do not hesitate to contact me for further information.  
Yours sincerely, 
Valeria Bortolaia 
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EQAS 2011: list of participants including the strains analyzed by each laboratory
Institute  Country E. coli Staphylococci Enterococci 
Austrian Agency for Health and Food Safety Austria X X X
Institute of Public Health Belgium X X
NRL AR on food, Nayional Diagnostic and Research Veterinary Institute Bulgaria X X X
Veterinary Services Cyprus X X X
State Veterinary Institute Prague Czech Republic X X X
DTU National Food Institute Denmark X X X
Estonian Veterinary and Food Laboratory Estonia X X X
Finnish Food Safety Authority EVIRA Finland X X X
Agence nationale de sécurité sanitaire ANSES -  Maisons Alfort - LERQAP France X
Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France X X
Agence nationale de sécurité sanitaire ANSES - Lyon France X X X
Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France X X
Federal Institute for Risk Assessment Germany X X X
Veterinary Laboratory of Chalkis Greece X X X
Central Agricultural Office Veterinary Diagnostic Directorate Hungary X X X
Central Veterinary Research Laboratory Ireland X X X
Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy X X
Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia X X X
National Veterinary Laboratory Lithuania X X X
Public Health Laboratory Malta X X X
Food and Consumer Product Safety Authority (VWA) The Netherlands X X X
Central Veterinary Institute of Wageningen UR The Netherlands X X X
Veterinærinstituttet Norway X X X
National Veterinary Research Institute Poland X X X
Laboratorio National de Investigacáo Veterinaria Portugal X X X
National Institute of R/D for Microbiology and Immunology “Cantacuzino” Romania X X X
Institute for Hygiene and Veterinary Public Health Romania X X X
Institute of Veterinary Medicine of Serbia Serbia X X X
State Veterinary and Food Institute  (SVFI) Slovakia X X X
National Veterinary Institute Slovenia X X
Laboratorio Central de Sanidad, Animal de Santa Fe Spain X
Laboratorio Central de Sanidad, Animal de Algete Spain X
VISAVET Health Surveillance Center, Complutense University Spain X X X
*CN de Alimentacion. Agencia Espanola de Seguridad Alimentria y Nutricion Spain
National Veterinary Institute, SVA Sweden X X X
Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland X X X
Centre for Infections Health Protection Agency United Kingdom X X X
The Veterinary Laboratory Agency United Kingdom X X X
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EQAS 2011 - EnterococcI test strains: expected results (MIC values and related interpretations)
Isolate ID Species
AMP CHL CIP ERY GEN LZD STR Q-D TET VAN
EURL ENT 5.1 E. faecalis ≤ 2 = 64 = 1 > 32 > 1024 = 2 > 2048 - > 32 ≤ 1
EURL ENT 5.2 E. faecium ≤ 2 = 4 = 1 = 4 ≤ 16 = 2 ≤ 64 = 1 ≤ 1 ≤ 1
EURL ENT 5.3 E. faecium = 4 = 8 ≤ 0.5 = 2 ≤ 16 = 2 ≤ 64 = 2 > 32 > 32
EURL ENT 5.4 E. faecium > 32 = 16 = 2 > 32 ≤ 16 = 2 > 2048 = 0.5 > 32 = 16
EURL ENT 5.5 E. faecalis ≤ 2 = 8 ≤ 0.5 > 32 ≤ 16 = 1 > 2048 - = 32 = 2
EURL ENT 5.6 E. faecium ≤ 2 = 8 = 1 > 32 ≤ 16 = 1 = 1024 = 8 ≤ 1 ≤ 1
EURL ENT 5.7 E. faecalis ≤ 2 = 4 = 1 = 1 ≤ 16 = 2 = 128 - ≤ 1 = 2
EURL ENT 5.8 E. faecalis ≤ 2 = 64 = 1 > 32 ≤ 16 = 2 > 2048 - > 32 ≤ 1
Isolate ID Species
AMP CHL CIP ERY GEN LZD STR Q-D TET VAN
EURL ENT 5.1 E. faecalis SUSC RESIST SUSC RESIST RESIST SUSC RESIST not applicable RESIST SUSC
EURL ENT 5.2 E. faecium SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC
EURL ENT 5.3 E. faecium SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC RESIST RESIST
EURL ENT 5.4 E. faecium RESIST SUSC SUSC RESIST SUSC SUSC RESIST SUSC RESIST RESIST
EURL ENT 5.5 E. faecalis SUSC SUSC SUSC RESIST SUSC SUSC RESIST not applicable RESIST SUSC
EURL ENT 5.6 E. faecium SUSC SUSC SUSC RESIST SUSC SUSC RESIST RESIST SUSC SUSC
EURL ENT 5.7 E. faecalis SUSC SUSC SUSC SUSC SUSC SUSC SUSC not applicable SUSC SUSC
EURL ENT 5.8 E. faecalis SUSC RESIST SUSC RESIST SUSC SUSC RESIST not applicable RESIST SUSC
RESIST
AMP, ampicillin LZD, linezolid
CHL, chloramphenicol STR, streptomycin
CIP, ciprofloxacin Q-D, quinupristin-dalfopristin (synercid)
ERY, erythromycin TET, tetracyclin
GEN, gentamicin VAN, vancomycin
Antimicrobial
Antimicrobial
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EQAS 2011 - Staphylococcus aureus test strains: expected results (MIC values and related interpretations)
Isolate ID mecA
CHL CIP ERY FFN FOX GEN PEN STR SMX TET TMP
EURL ST 5.1 = 4 = 2 ≤ 0.25 = 4 = 8 > 16 > 16 > 64 = 512 = 32 ≤ 0.5 pos.
EURL ST 5.2 > 64 = 0.5 > 16 > 64 = 4 ≤ 0.25 > 16 > 64 ≤ 32 ≤ 0.5 = 1 neg.
EURL ST 5.3 = 8 = 0.5 = 0.5 = 4 = 2 ≤ 0.25 ≤ 0.06 ≤ 4 ≤ 32 ≤ 0.5 = 1 neg.
EURL ST 5.4 = 8 = 0.5 > 16 = 4 = 2 ≤ 0.25 = 16 > 64 ≤ 32 = 32 = 1 neg.
EURL ST 5.5 = 8 > 8 = 0.5 = 4 = 16 ≤ 0.25 = 8 > 64 ≤ 32 > 32 > 32 pos.
EURL ST 5.6 = 4 = 0.5 ≤ 0.25 = 2 = 2 ≤ 0.25 = 0.5 = 8 ≤ 32 = 8 ≤ 0.5 neg.
EURL ST 5.7 = 8 = 0.5 = 0.5 = 4 = 4 ≤ 0.25 = 4 > 64 ≤ 32 > 32 > 32 neg.
EURL ST 5.8 = 8 = 0.5 = 0.5 = 4 = 16 = 0.5 = 16 > 64 ≤ 32 > 32 > 32 pos.
Isolate ID mecA
CHL CIP ERY FFN FOX GEN PEN STR SMX TET TMP
EURL ST 5.1 SUSC RESIST SUSC SUSC RESIST RESIST RESIST RESIST RESIST RESIST SUSC pos.
EURL ST 5.2 RESIST SUSC RESIST RESIST SUSC SUSC RESIST RESIST SUSC SUSC SUSC neg.
EURL ST 5.3 SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC neg.
EURL ST 5.4 SUSC SUSC RESIST SUSC SUSC SUSC RESIST RESIST SUSC RESIST SUSC neg.
EURL ST 5.5 SUSC RESIST SUSC SUSC RESIST SUSC RESIST RESIST SUSC RESIST RESIST pos.
EURL ST 5.6 SUSC SUSC SUSC SUSC SUSC SUSC RESIST SUSC SUSC RESIST SUSC neg.
EURL ST 5.7 SUSC SUSC SUSC SUSC SUSC SUSC RESIST RESIST SUSC RESIST RESIST neg.
EURL ST 5.8 SUSC SUSC SUSC SUSC RESIST SUSC RESIST RESIST SUSC RESIST RESIST pos.
CHL, chloramphenicol GEN, gentamicin RESIST
CIP, ciprofloxacin PEN, penicillin
ERY, erythromycin STR, streptomycin
FFN, florfenicol STX, sulphamethoxazole
FOX, cefoxitin TET, tetracycline
TMP, trimethoprim
Antimicrobial
Antimicrobial
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EQAS 2011 - Escherichia coli test strains: expected results (MIC values and related interpretations) 
Isolate ID NOTE
AMP CAZ CHL CIP CTX FFN FOX GEN NAL SMX STR TET TMP XNL CAZ/CAZ+CLA CTX/CTX+CLA IP/IPI
EURL EC 5.1 = 4 = 0.25 = 8 = 0.5 ≤ 0.12 = 8 = 4 = 1 = 16 ≤ 64 > 128 > 32 ≤ 1 ≤ 0.5
EURL EC 5.2 > 32 = 0.125 = 4 ≤ 0.015 ≤ 0.12 = 4 = 4 = 16 ≤ 4 ≤ 64 > 128 > 32 ≤ 1 ≤ 0.5
EURL EC 5.3 > 32 = 0.25 > 64 = 0.25 ≤ 0.12 = 8 = 4 = 1 > 64 > 1024 > 128 > 32 > 32 ≤ 0.5
EURL EC 5.4 > 32 = 1 = 4 = 0.5 > 16 = 8 = 4 ≥ 16 = 16 > 1024 > 128 > 32 > 32 > 8 MIC ratio < 8 MIC ratio ≥ 8 MIC ratio < 8 ESBL
EURL EC 5.5 > 32 = 4 = 4 ≤ 0.015 = 32 = 4 = 4 = 1 ≤ 4 ≤ 64 ≤ 8 ≤ 2 ≤ 1 > 8 MIC ratio ≥ 8 MIC ratio ≥ 8 MIC ratio < 8 ESBL
EURL EC 5.6 > 32 = 0.064 = 32 = 0.06 ≤ 0.12 = 8 = 4 = 16 = 32 > 1024 = 128 > 32 > 32 ≤ 0.5
EURL EC 5.7 = 4 = 0.125 = 8 < 0.015 ≤ 0.12 = 8 = 4 = 1 ≤ 4 ≤ 64 ≤ 8 ≤ 2 ≤ 1 ≤ 0.5
EURL EC 5.8 > 32 = 2 = 8 = 2 = 1 = 8 > 8 ≤ 0.5 > 64 ≤ 64 ≤ 8 ≤ 2 ≤ 1 = 1 MIC ratio < 8 MIC ratio < 8 AmpC
Isolate ID NOTE
AMP CAZ CHL CIP CTX FFN FOX GEN NAL SMX STR TET TMP XNL CAZ/CAZ+CLA CTX/CTX+CLA IP/IPI
EURL EC 5.1 SUSC SUSC SUSC RESIST SUSC SUSC SUSC SUSC SUSC SUSC RESIST RESIST SUSC SUSC
EURL EC 5.2 RESIST SUSC SUSC SUSC SUSC SUSC SUSC RESIST SUSC SUSC RESIST RESIST SUSC SUSC
EURL EC 5.3 RESIST SUSC RESIST RESIST SUSC SUSC SUSC SUSC RESIST RESIST RESIST RESIST RESIST SUSC
EURL EC 5.4 RESIST RESIST SUSC RESIST RESIST SUSC SUSC RESIST SUSC RESIST RESIST RESIST RESIST RESIST no synergy phantom no synergy ESBL
EURL EC 5.5 RESIST RESIST SUSC SUSC RESIST SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC RESIST phantom synergy no synergy ESBL
EURL EC 5.6 RESIST SUSC RESIST RESIST SUSC SUSC SUSC RESIST RESIST RESIST RESIST RESIST RESIST SUSC
EURL EC 5.7 SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC SUSC
EURL EC 5.8 RESIST RESIST SUSC RESIST RESIST SUSC RESIST SUSC RESIST SUSC SUSC SUSC SUSC SUSC no synergy no synergy AmpC
AMP, ampicillin FOX, cefoxitin TMP, trimethoprim RESIST
CAZ, ceftazidime GEN, gentamicin XNL, ceftiofur
CHL, chloramphenicol NAL, nalidixic acis CAZ+CLA, ceftazidime + clavulanic acid
CIP, ciprofloxacin SMX, sulphamethoxazole CTX+CLA, cefotaxime + clavulanic acid
CTX, cefotaxime STR, streptomycin IP, imipenem
FFN, florfenicol TET, tetracycline IPI, imipenem + EDTA
MIC (μg/mL)
MIC (μg/mL)
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PROTOCOL  
For antimicrobial susceptibility testing of Escherichia coli, enterococci and staphylococci 
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3.1 Shipping, receipt and storage of strains ------------------------------------------------------------------ 2 
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5. HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE ------------------------------- 6 
 
 
1. Introduction 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of E. coli, enterococci and staphylococci is among the 
tasks of the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The EC/Ent/Staph 
EQAS 2011 will include AST of eight E. coli, eight enterococci and eight staphylococci strains and 
AST of reference strains E. coli ATCC 25922 (CCM 3954), E. faecalis ATCC 29212 (CCM 4224), 
S. aureus ATCC 25923 (CCM 3953) (for disk diffusion) and S. aureus ATCC 29213 (CCM 4223) 
(for MIC). 
 
The above-mentioned reference strains are included in the parcel only for new participants in the 
EQAS who did not receive them previously. The reference strains are original certified cultures and 
are free of charge. Please take proper care of these strains, and handle and maintain them according 
to the instructions reported in the manual ‘Subculture and Maintenance of QC Strains’. Please use 
the reference strains for future internal quality control when performing AST in your laboratory. 
 
2. Objectives 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to E. coli, 
enterococci and staphylococci. Further objectives are to evaluate and improve the comparability of 
surveillance data on antimicrobial susceptibility of E. coli, enterococci and staphylococci reported 
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to EFSA by different laboratories, and to harmonise the breakpoints for antimicrobial susceptibility 
used within the EU. 
 
3. Outline of the EC/Ent/Staph EQAS 2011 
 
3.1 Shipping, receipt and storage of strains 
In June 2011, the EU-appointed National Reference Laboratories for Antimicrobial Resistance will 
receive a parcel containing eight E. coli, eight enterococci and eight staphylococci strains from the 
National Food Institute, Denmark. This parcel will also contain reference strains, but only for 
participants who did not receive them previously. All strains are non-toxin-producing human 
pathogens Class II, and extended-spectrum beta-lactamase (ESBL)-producing strains and 
methicillin-resistant Staphylococcus aureus (MRSA) strains could be included. 
The reference strains are shipped lyophilised, while the test strains are stab cultures. On arrival, the 
stab cultures must be subcultured and all cultures should be kept refrigerated until testing. 
Lyophilised reference strains should be revived by following the procedure reported in the link 
below. 
 
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ reported 
on the EURL-AR website (www.eurl-ar.eu). 
 
3.3 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in tables 1, 2 and 3 by 
using the method implemented in your laboratory for performing monitoring for EFSA. 
Participants performing minimum inhibitory concentration (MIC) determination should use the 
values listed in tables 1, 2 and 3 for interpretation of results. These values represent the 
epidemiological cut-off values developed by EUCAST (www.eucast.org), and allow categorisation 
of bacterial strains into two categories: resistant and susceptible. A categorization as intermediate is 
not accepted, and “intermediate strains” should be interpreted as susceptible. 
Participants using disk diffusion are recommended to interpret the results according to the 
breakpoints used routinely. Strains must be categorised into resistant and susceptible. Also in this 
case, a categorization as intermediate is not accepted, and “intermediate strains” should be 
interpreted as susceptible. 
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TABLE 1. 
Antimicrobials recommended for AST of Escherichia coli and interpretative breakpoints 
 
Antimicrobials for E. coli AST MIC (g/mL) R is > 
Ampicillin, AMP 8 
Cefotaxime, CTX 0.25 
Cefoxitin, FOX 8 
Ceftazidime, CAZ 0.5 
Ceftiofur, XNL 1 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 0.032 
Florfenicol, FFN 16 
Gentamicin, GEN 2 
Nalidixic acid, NAL 16 
Streptomycin, STR 8* 
Sulfonamides, SMX 256** 
Tetracycline, TET 8 
Trimethoprim, TMP 2 
*Based on studies performed by the EURL-AR network (manuscript accepted for publication in Microbial Drug Resistance) 
**CLSI M100 Table 2A 
Important notes: beta-lactam resistance 
Confirmatory tests for ESBL production is mandatory on all strains resistant to cefotaxime 
(CTX), ceftazidime (CAZ) and/or ceftiofur (XNL). 
Confirmatory test for ESBL production requires use of both cefotaxime (CTX) and 
ceftazidime (CAZ) alone and in combination with a -lactamase inhibitor (clavulanic acid). 
Synergy is defined either as i) a ≥ 3 twofold concentration decrease in an MIC for either 
antimicrobial agent tested in combination with clavulanic acid vs. its MIC when tested alone (E-test 
3 dilution steps difference; MIC CTX : CTX/CL or CAZ : CAZ/CL ratio  8) or ii) a  5 mm 
increase in a zone diameter for either antimicrobial agent tested in combination with clavulanic acid 
vs. its zone when tested alone (CLSI M100 Table 2A; Enterobacteriaceae). The presence of synergy 
indicates ESBL production. 
Confirmatory test for Metallo-beta-lactamase (MBL) production requires use of imipenem 
(IMI) and IMI/EDTA. Synergy is defined as a ≥ 3 twofold concentration decrease in the MIC for 
the combination IMI/EDTA vs. MIC for IMI alone (E-test 3 dilution steps difference, MIC IMI : 
IMI/EDTA ratio  8; CLSI M100, Table 2A; Enterobacteriaceae). The presence of synergy 
indicates MBL production. 
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Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase, that should be verified by PCR and sequencing. 
The EURL-AR aims to harmonise with EUCAST expert rules. Accordingly, MIC values and 
relative interpretation of cefotaxime, ceftazidime and/or ceftiofur used for detection of beta-
lactamase-producing strains in this EQAS should be reported as found.  
 
TABLE 2. 
Antimicrobials recommended for AST of Enterococcus spp. and interpretative breakpoints 
 
Antimicrobials for enterococci AST MIC (g/mL) R is > 
MIC (g/mL) 
R is > 
 E. faecium E. faecalis 
Ampicillin, AMP 4 4 
Chloramphenicol, CHL 32 32 
Ciprofloxacin, CIP 4 4 
Erythromycin, ERY 4 4 
Gentamicin, GEN 32 32 
Linezolid, LZD 4 4 
Streptomycin, STR 128 512 
Quinupristin-dalfopristin (Synercid), SYN 4* Not applicable 
Tetracycline, TET 4 4 
Vancomycin, VAN 4 4 
*DANMAP 2009 (www.danmap.org)  
Important notes: identity of the test strains 
Please refer to the test forms for the species (E. faecalis or E. faecium) of the test strains.  
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TABLE 3. 
Antimicrobials recommended for AST of Staphylococcus aureus and interpretative breakpoints 
  
Antimicrobials for S. aureus AST MIC (g/mL) R is > 
Cefoxitin, FOX 4 
Chloramphenicol, CHL 16 
Ciprofloxacin, CIP 1 
Erythromycin, ERY 1 
Florfenicol, FFN 8 
Gentamicin, GEN 2 
Penicillin, PEN 0.125* 
Streptomycin, STR 16 
Sulfonamides, SMX 128 
Tetracycline, TET 1 
Trimethoprim, TMP 4 
*CLSI M100 Table 2C 
Important notes: MRSA 
Some test strains may be methicillin-resistant. Confirmation of mecA presence is mandatory in 
this EQAS. For this purpose, you are welcome to use the method you prefer, and upload the result 
as ‘positive’ or ‘negative’. According to CLSI recommendations (M100, Table 2C), all MRSA 
should be regarded as resistant to all β-lactam antibiotics. 
 
4. Reporting of results and evaluation 
Please write your results in the test forms, and enter your results into the interactive web database. 
In addition, we kindly ask you to report in the database the tested MIC range and/or antimicrobial 
disk content. Finally, if you did not use the cut-off values recommended in the protocol for 
interpretation of AST results, please report the breakpoints used in the database. 
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than 9 September 2011. After 
the deadline, the database will be closed and you will be able to view and print an automatically 
generated report evaluating your results. Results in agreement with the expected interpretation are 
categorised as ‘correct’, while results deviating from the expected interpretation are categorised as 
‘incorrect’. 
If you do not have access to the Internet, or if you experience difficulties in entering your results, 
please return the completed test forms by e-mail, fax or mail to the National Food Institute, 
Denmark.  
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All results will be summarised in a report available to all participants. The data in the report will be 
presented with laboratory codes. A laboratory code is only known to the individual laboratory, 
while the complete list of laboratories and their respective codes is confidential and only known to 
the EURL-AR and the EU Commission. All conclusions will be public. 
If you have any question, please do not hesitate to contact: 
Valeria Bortolaia 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204 
DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6284 
Fax: +45 3588 6341 
E-mail: vabo@food.dtu.dk 
 
5. How to enter results in the interactive database 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms and the breakpoint values you used.  
Enter the EURL-AR EQAS 2011 start web page (http://thor.dfvf.dk/crl), write your username and 
password in lower-cases and press enter. Your username and password are the same used in the 
previous EQAS’s arranged by The National Food Institute, Denmark. Do not hesitate to contact us 
if you experience problems with the login. 
You can browse back and forth by using the back and forward keys and by clicking on the EURL 
logo. 
Click on either “E. coli test results”, “enterococci test results” or “staphylococci test results” based 
on the results you are going to upload. The description reported below is based on Salmonella test 
result entry, but it is the exact same procedure for entering E. coli, enterococci and staphylococci 
test results. 
Click on "Start of Data Entry - Methods and Breakpoints for Salm.” 
In the next page, you can navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing of Salmonella 
and the brand of discs, tablets, MIC trays, etc.  
Fill in the fields related to either antimicrobial disk content or tested MIC range. If you used disk 
diffusion, please upload the breakpoints used for interpretation of results. 
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Click on "save and go to next page”  
In the data entry pages, enter the obtained values and the interpretation (R, resistant or S, 
susceptible) for each E. coli, enterococcus and staphylococcus strain. 
For E. coli strains, remember to report also the results for the ESBL detection tests. 
For S. aureus strains, remember to report also the results for presence/absence of mecA. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter the zone diameters in mm and MIC 
values in µg/ml. Remember to use the operator keys to show symbols like “equal to”, etc... If you 
do not use CLSI guidelines for AST of the reference strains, please add a comment on the method 
used. 
Click on "save and go to next page" 
This page is a menu that allows you to review the input pages and approve your input. 
Browse through the pages and make corrections if necessary. Remember to save a page if you make 
corrections. If you save a page without changes, you will see an error screen. In this case, click on 
"back" to get back to the page and "go to next page" to continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields because 
YOU CAN ONLY APPROVE ONCE! The approval blocks your data entry in the interactive 
database.  
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Appendix 5a. Breakpoints used routinely in disk diffusion - Enterococci
15 16 19
18 8 10
26 16 17
40 16 17
18 18 19
26 15 21
40 15 21
15 17 22
18 17 18
26 13 23
40 13 23
15 17 17
18 13 14
26 12 15
40 12 15
15 24 24
18 18 19
26 20 23
40 20 23
15 12 14
18 11 12
26 6 10
40 11 15
18 21 22
26 15 19
15 17 19
18 16 17
26 14 19
40 14 16
15 17 17
18 11 12
26 14 17
40 14 17
Tetracycline, TET
Vancomycin, VAN
Ciprofloxacin, CIP
Erythromycin, ERY
Gentamicin, GEN
Linezolid, LZD
Streptomycin, STR
Quinupristin-dalfopristin, Q-D
Antimicrobial Lab. no. R <= (mm) S >=  (mm)
Ampicillin, AMP
Appendix 5b. Breakpoints used routinely in disk diffusion - Staphylococci
4 18
14 22 23
15 19 22
18 17 18
40 12 18
4 19
13 15 21
14 18 22
15 22 22
18 18 19
40 15 21
4 18 21
13 16 22
14 18 22
15 17 22
18 18 21
40 13 23
15 15 19
18 17 18
4 18
13 12 15
14 20
15 20 20
18 17 18
40 12 15
13 28 29
14 29
15 29 29
18 28 29
40 28 29
13 12 15
15 13 15
18 11 12
40 11 15
13 12 17
14 11 17
18 15 16
40 12 17
4 19 22
13 14 19
14 20 23
15 17 19
18 19 22
40 14 19
4 14 17
14 15 20
18 14 17
40 10 16
Tetracycline, TET
Trimethoprim, TMP
Erythromycin, ERY
Florfenicol, FFN
Gentamicin, GEN
Penicillin, PEN
Streptomycin, STR
Sulfamethoxazole, SMX
Chloramphenicol, CHL
Antimicrobial Lab. no. R <=  (mm) S >=  (mm)
Ciprofloxacin, CIP
Appendix 5c. Breakpoints used routinely in disk diffusion - Escherichia coli
14 19
15 14 21
18 13 14
40 13 17
14 26
15 22 26
18 17 21
40 14 23
14 26
15 18 26
18 17 21
40 14 18
14 21
15 17 21
18 19 20
14 23
15 18 22
18 16 17
40 12 18
14 25
15 21 25
18 18 22
40 15 21
15 14 19
18 16 17
14 18
15 15 18
18 13 17
40 12 18
14 20
15 14 20
18 15 16
40 13 19
15 12 15
18 10 11
40 11 15
14 17
15 9 16
18 13 14
40 12 17
14 19
15 16 19
18 14 15
40 11 15
14 20
15 11 16
18 14 18
40 10 16
Nalidixic acid, NAL
Streptomycin, STR
Sulfamethoxazole, SMX
Tetracycline,TET
Trimethoprim, TMP
Ceftazidime, CAZ
Ceftiofur, XNL
Chloramphenicol, CHL
Ciprofloxacin, CIP
Florfenicol, FFN
Gentamicin, GEN
Antimicrobial Lab. no. R <= (mm) S >= (mm)
Ampicillin, AMP
Cefotaxime, CTX
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Antimicrobial MIC*
Ampicillin, AMP 0.5 - 2
Avilamycin, AVI 0.5 - 4
Chloramphenicol, CHL 4 - 16
Ciprofloxacin, CIP 0.25 - 2
Daptomycin, DAP 1 - 8
Erythromycin, ERY 1 - 4
Florfenicol, FFN 2 - 8
Gentamicin, GEN 4 - 16
Linezolid, LZD 1 - 4
Quinupristin-dalfopristin, Q-D 2 - 8
Tetracycline, TET 8 - 32
Tigecycline, TGC 0.03 - 0.12
Vancomycin, VAN 1 - 4
ATCC 29213 
Antimicrobial Disk diffusion* ROSCO MIC* 
Chloramphenicol, CHL 16 - 26 None 2 - 8
Ciprofloxacin, CIP 22 - 30 21 - 29 0.12 - 0.5
Erythromycin, ERY 22 - 30 26 - 33 0.25 - 1
Florfenicol, FFN None None 2 - 8
Gentamicin, GEN 19 - 27 25 - 32 0.12 - 1
Penicillin, PEN 26 - 37 None 0.25 - 2
Streptomycin, STR 14 - 22 None None
Sulphonamides, SMX 24 - 30 26 - 34 32 - 128
Tetracycline, TET 24 - 34 23 - 33 0.12 - 1
Trimethoprim, TMP 19 - 26 19 - 25 1-4
Antimicrobial Disk diffusion* MIC*
Amoxicillin cl., AUG 18 - 24 2 - 8
Ampicillin, AMP 16 - 22 2 - 8
Cefotaxime, CTX 29 - 35 0.03 - 0.12
Cefpodoxime, POD 23 - 28 0.25 - 1
Ceftazidime, CAZ 25 - 32 0.06 - 0.5
Ceftiofur, XNL 26 - 31 0.25 - 1
Chloramphenicol, CHL 21 - 27 2 - 8
Ciprofloxacin, CIP 30 - 40 0.004 - 0.015
Florfenicol, FFN 22 - 28 2 - 8
Gentamicin, GEN 19 - 26 0.25 - 1
Nalidixic acid, NAL 22 - 28 1 - 4
Streptomycin, STR None 4 - 16
Sulphonamides, SMX 15 - 23 8 - 32
Tetracycline, TET 18 - 25 0.5 - 2
Trimethoprim, TMP 21 - 28 0.5 - 2
Enterococcus faecalis  ATCC 29212
Escherichia coli  ATCC 25922
ATCC 25923
*MIC ranges (in  µg/ml)  and disk diffusion ranges (in mm) according to CLSI M100-S21 
with the exception of the MIC range for streptomycin which is according to Sensititre. In 
addition, the range for ciprofloxacin is extended to include 0.016 µg/ml
Staphylococcus aureus
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Appendix 7a. Summary of obtained and expected results in the enterococci trial 
Strain Antimicrobial Expected 
results
% R % S Number of 
expected 
results
Number of results 
deviating from 
expected
EURL ENT 5.1 Ampicillin , AMP S 4 96 23 1
Chloramphenicol, CHL R 88 12 23 3
Ciprofloxacin , CIP S 5 95 21 1
Erythromycin, ERY R 100 0 27 0
Gentamicin, GEN R 100 0 27 0
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D - 50 50 - 2
Streptomycin, STR R 100 0 26 0
Tetracycline, TET R 100 0 27 0
Vancomycin, VAN S 4 96 26 1
TOTAL 221 9
EURL ENT 5.2 Ampicillin , AMP S 8 92 22 2
Chloramphenicol, CHL S 0 100 26 0
Ciprofloxacin , CIP S 9 91 20 2
Erythromycin, ERY S 46 54 14 12
Gentamicin, GEN S 8 92 24 2
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D S 0 100 14 0
Streptomycin, STR S 15 85 22 4
Tetracycline, TET S 4 96 26 1
Vancomycin, VAN S 0 100 27 0
TOTAL 221 9
EURL ENT 5.3 Ampicillin , AMP S 8 92 22 2
Chloramphenicol, CHL S 0 100 26 0
Ciprofloxacin , CIP S 5 95 21 1
Erythromycin, ERY S 7 93 25 2
Gentamicin, GEN S 4 96 24 1
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D S 8 92 12 1
Streptomycin, STR S 8 92 23 2
Tetracycline, TET R 96 4 26 1
Vancomycin, VAN R 96 4 26 1
TOTAL 221 9
EURL ENT 5.4 Ampicillin , AMP R 96 4 23 1
Chloramphenicol, CHL S 4 96 25 1
Ciprofloxacin , CIP S 14 86 19 3
Erythromycin, ERY R 96 4 26 1
Gentamicin, GEN S 15 85 22 4
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D S 0 100 14 0
Streptomycin, STR R 100 0 25 0
Tetracycline, TET R 100 0 27 0
Vancomycin, VAN R 89 11 24 3
TOTAL 221 9
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Strain Antimicrobial Expected 
results
% R % S Number of 
expected 
results
Number of results 
deviating from 
expected
EURL ENT 5.5 Ampicillin , AMP S 4 96 23 1
Chloramphenicol, CHL S 0 100 26 0
Ciprofloxacin , CIP S 5 95 21 1
Erythromycin, ERY R 100 0 27 0
Gentamicin, GEN S 8 92 24 2
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D - 50 50 - 2
Streptomycin, STR R 100 0 26 0
Tetracycline, TET R 100 0 27 0
Vancomycin, VAN S 4 96 26 1
TOTAL 221 9
EURL ENT 5.6 Ampicillin , AMP S 13 87 20 3
Chloramphenicol, CHL S 0 100 26 0
Ciprofloxacin , CIP S 14 86 19 3
Erythromycin, ERY R 100 0 27 0
Gentamicin, GEN S 8 92 23 2
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D R 62 38 8 5
Streptomycin, STR R 80 20 20 5
Tetracycline, TET S 4 96 26 1
Vancomycin, VAN S 4 96 26 1
TOTAL 221 9
EURL ENT 5.7 Ampicillin , AMP S 4 96 23 1
Chloramphenicol, CHL S 0 100 26 0
Ciprofloxacin , CIP S 9 91 20 2
Erythromycin, ERY S 7 93 25 2
Gentamicin, GEN S 12 88 22 3
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D - 50 50 - 2
Streptomycin, STR S 15 85 22 4
Tetracycline, TET S 7 93 25 2
Vancomycin, VAN S 4 96 26 1
TOTAL 221 9
EURL ENT 5.8 Ampicillin , AMP S 4 96 23 1
Chloramphenicol, CHL R 92 8 24 2
Ciprofloxacin , CIP S 5 95 21 1
Erythromycin, ERY R 100 0 27 0
Gentamicin, GEN S 12 88 22 3
Linezolid, LZD S 5 95 21 1
Quinu-dalfo-pristin, Q-D - 50 50 - 2
Streptomycin, STR R 100 0 26 0
Tetracycline, TET R 100 0 27 0
Vancomycin, VAN S 4 96 26 1
TOTAL 221 9
Suceptibility tests resulted in deviations from expected results
Appendix 7a, page 2 of 2
Appendix 7b. Summary of obtained and expected results in the staphylococci trial 
Strain Antimicrobial Expected 
results
% R % S Number of 
expected 
results
Number of results 
deviating from 
expected
EURL ST 5.1 Cefoxitin, FOX R 97 3 28 1
Chloramphenicol, CHL S 3 97 29 1
Ciprofloxacin, CIP R 34 66 10 19
Erythromycin, ERY S 0 100 32 0
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN R 97 3 30 1
Penicillin, PEN R 100 0 31 0
Streptomycin, STR R 100 0 24 0
Sulfamethoxazole, SMX R 87 13 20 3
Tetracycline, TET R 97 3 30 1
Trimethoprim, TMP S 0 100 27 0
TOTAL 272 26
EURL ST 5.2 Cefoxitin, FOX S 3 97 28 1
Chloramphenicol, CHL R 97 3 29 1
Ciprofloxacin, CIP S 0 100 30 0
Erythromycin, ERY R 97 3 31 1
Florfenicol, FFN R 100 0 11 0
Gentamicin, GEN S 3 97 30 1
Penicillin, PEN R 97 3 30 1
Streptomycin, STR R 100 0 24 0
Sulfamethoxazole, SMX S 23 77 17 5
Tetracycline, TET S 3 97 30 1
Trimethoprim, TMP S 7 93 25 2
TOTAL 285 13
EURL ST 5.3 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP S 0 100 30 0
Erythromycin, ERY S 0 100 32 0
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN S 3 97 30 1
Penicillin, PEN S 0 100 30 0
Streptomycin, STR S 0 100 24 0
Sulfamethoxazole, SMX S 13 88 21 3
Tetracycline, TET S 3 97 30 1
Trimethoprim, TMP S 7 93 25 2
TOTAL 292 7
EURL ST 5.4 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP S 0 100 30 0
Erythromycin, ERY R 100 0 32 0
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN S 0 100 31 0
Penicillin, PEN R 100 0 31 0
Streptomycin, STR R 100 0 24 0
Sulfamethoxazole, SMX S 4 96 22 1
Tetracycline, TET R 97 3 30 1
Trimethoprim, TMP S 4 96 25 1
TOTAL 295 3
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Strain Antimicrobial Expected 
results
% R % S Number of 
expected 
results
Number of results 
deviating from 
expected
EURL ST 5.5 Cefoxitin, FOX R 97 3 28 1
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP R 100 0 30 0
Erythromycin, ERY S 3 97 31 1
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN S 0 100 31 0
Penicillin, PEN R 100 0 31 0
Streptomycin, STR R 100 0 24 0
Sulfamethoxazole, SMX S 0 100 23 0
Tetracycline, TET R 100 0 31 0
Trimethoprim, TMP R 100 0 26 0
TOTAL 296 2
EURL ST 5.6 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP S 0 100 30 0
Erythromycin, ERY S 0 100 32 0
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN S 0 100 31 0
Penicillin, PEN R 97 3 29 1
Streptomycin, STR S 0 100 24 0
Sulfamethoxazole, SMX S 4 96 22 1
Tetracycline, TET R 97 3 30 1
Trimethoprim, TMP S 4 96 25 1
TOTAL 293 4
EURL ST 5.7 Cefoxitin, FOX S 0 100 29 0
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP S 0 100 30 0
Erythromycin, ERY S 0 100 32 0
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN S 0 100 31 0
Penicillin, PEN R 100 0 31 0
Streptomycin, STR R 100 0 24 0
Sulfamethoxazole, SMX S 4 96 22 1
Tetracycline, TET R 97 3 30 1
Trimethoprim, TMP R 100 0 26 0
TOTAL 296 2
EURL ST 5.8 Cefoxitin, FOX R 97 3 28 1
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP S 0 100 30 0
Erythromycin, ERY S 0 100 32 0
Florfenicol, FFN S 0 100 11 0
Gentamicin, GEN S 0 100 31 0
Penicillin, PEN R 100 0 31 0
Streptomycin, STR R 96 4 23 1
Sulfamethoxazole, SMX S 4 96 22 1
Tetracycline, TET R 100 0 31 0
Trimethoprim, TMP R 100 0 26 0
TOTAL 295 3
Suceptibility tests resulted in deviations from expected results
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Appendix 7c. Summary of obtained and expected results in the Escherichia coli trial 
Strain Antimicrobial Expected 
results
% R % S Number of 
expected 
results
Number of results 
deviating from 
expected
EURL EC 5.1 Ampicillin, AMP S 0 100 30 0
Cefotaxime, CTX S 0 100 31 0
Ceftazidime, CAZ S 7 93 27 2
Ceftiofur, XNL S 0 100 9 0
Chloramphenicol, CHL S 0 100 31 0
Ciprofloxacin, CIP R 90 10 28 3
Florfenicol, FFN S 0 100 27 0
Gentamicin, GEN S 0 100 32 0
Nalidixic acid, NAL S 16 84 26 5
Streptomycin, STR R 94 6 29 2
Sulfamethoxazole, SMX S 0 100 29 0
Tetracycline, TET R 97 3 31 1
Trimethoprim, TMP S 3 97 28 1
TOTAL 358 14
EURL EC 5.2 Ampicillin, AMP R 100 0 30 0
Cefotaxime, CTX S 0 100 31 0
Ceftazidime, CAZ S 0 100 29 0
Ceftiofur, XNL S 0 100 9 0
Chloramphenicol, CHL S 0 100 31 0
Ciprofloxacin, CIP S 0 100 31 0
Florfenicol, FFN S 4 96 26 1
Gentamicin, GEN R 94 6 30 2
Nalidixic acid, NAL S 0 100 31 0
Streptomycin, STR R 100 0 31 0
Sulfamethoxazole, SMX S 0 100 29 0
Tetracycline, TET R 97 3 31 1
Trimethoprim, TMP S 0 100 29 0
TOTAL 368 4
EURL EC 5.3 Ampicillin, AMP R 100 0 30 0
Cefotaxime, CTX S 0 100 31 0
Ceftazidime, CAZ S 3 97 28 1
Ceftiofur, XNL S 0 100 9 0
Chloramphenicol, CHL R 100 0 31 0
Ciprofloxacin, CIP R 94 6 29 2
Florfenicol, FFN S 0 100 27 0
Gentamicin, GEN S 0 100 32 0
Nalidixic acid, NAL R 100 0 31 0
Streptomycin, STR R 100 0 31 0
Sulfamethoxazole, SMX R 100 0 29 0
Tetracycline, TET R 100 0 32 0
Trimethoprim, TMP R 97 3 28 1
TOTAL 368 4
EURL EC 5.4 Ampicillin, AMP R 100 0 30 0
Cefotaxime, CTX R 100 0 31 0
Ceftazidime, CAZ R 38 62 11 18
Ceftiofur, XNL R 100 0 9 0
Chloramphenicol, CHL S 3 97 30 1
Ciprofloxacin, CIP R 90 10 28 3
Florfenicol, FFN S 4 96 26 1
Gentamicin, GEN R 97 3 31 1
Nalidixic acid, NAL S 16 84 26 5
Streptomycin, STR R 100 0 31 0
Sulfamethoxazole, SMX R 100 0 29 0
Tetracycline, TET R 100 0 32 0
Trimethoprim, TMP R 100 0 29 0
TOTAL 343 29
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Strain Antimicrobial Expected 
results
% R % S Number of 
expected 
results
Number of results 
deviating from 
expected
EURL EC 5.5 Ampicillin, AMP R 100 0 30 0
Cefotaxime, CTX R 100 0 31 0
Ceftazidime, CAZ R 90 10 26 3
Ceftiofur, XNL R 100 0 9 0
Chloramphenicol, CHL S 3 97 30 1
Ciprofloxacin, CIP S 3 97 30 1
Florfenicol, FFN S 0 100 27 0
Gentamicin, GEN S 3 97 31 1
Nalidixic acid, NAL S 3 97 30 1
Streptomycin, STR S 3 97 30 1
Sulfamethoxazole, SMX S 3 97 28 1
Tetracycline, TET S 3 97 31 1
Trimethoprim, TMP S 4 96 27 1
TOTAL 360 11
EURL EC 5.6 Ampicillin, AMP R 100 0 30 0
Cefotaxime, CTX S 3 97 30 1
Ceftazidime, CAZ S 7 93 27 2
Ceftiofur, XNL S 0 100 9 0
Chloramphenicol, CHL R 94 6 29 2
Ciprofloxacin, CIP R 77 23 24 7
Florfenicol, FFN S 4 96 26 1
Gentamicin, GEN R 94 6 30 2
Nalidixic acid, NAL R 97 3 30 1
Streptomycin, STR R 100 0 31 0
Sulfamethoxazole, SMX R 100 0 29 0
Tetracycline, TET R 100 0 32 0
Trimethoprim, TMP R 100 0 29 0
TOTAL 356 16
EURL EC 5.7 Ampicillin, AMP S 3 97 29 1
Cefotaxime, CTX S 0 100 31 0
Ceftazidime, CAZ S 3 97 28 1
Ceftiofur, XNL S 0 100 9 0
Chloramphenicol, CHL S 0 100 31 0
Ciprofloxacin, CIP S 3 97 30 1
Florfenicol, FFN S 4 96 26 1
Gentamicin, GEN S 0 100 32 0
Nalidixic acid, NAL S 0 100 31 0
Streptomycin, STR S 3 97 30 1
Sulfamethoxazole, SMX S 0 100 29 0
Tetracycline, TET S 0 100 32 0
Trimethoprim, TMP S 0 100 29 0
TOTAL 367 5
EURL EC 5.8 Ampicillin, AMP R 100 0 29 0
Cefotaxime, CTX R 87 13 26 4
Ceftazidime, CAZ R 82 18 23 5
Ceftiofur, XNL S 0 100 7 0
Chloramphenicol, CHL S 0 100 30 0
Ciprofloxacin, CIP R 97 3 29 1
Florfenicol, FFN S 0 100 27 0
Gentamicin, GEN S 0 100 31 0
Nalidixic acid, NAL R 100 0 30 0
Streptomycin, STR S 3 97 29 1
Sulfamethoxazole, SMX S 0 100 28 0
Tetracycline, TET S 3 97 30 1
Trimethoprim, TMP S 29 71 20 8
TOTAL 339 20
Suceptibility tests resulted in deviations from expected results
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
4
Method 
used for 
AST
EURL ENT 5.2 Erythromycin, ERY
1 R 8.0 S = 4
EURL ENT 5.4 Gentamicin, GEN R 64 S <=16
EURL ENT 5.6 Quinu-dalfo-pristin, Q-D S 4.00 R = 8
EURL ENT 5.1 Chloramphenicol, CHL S 32 R = 64
EURL ENT 5.2 Erythromycin, ERY
1 R 8 S = 4
EURL ENT 5.3 Vancomycin, VAN S <=1 R > 32
EURL ENT 5.6 Quinu-dalfo-pristin, Q-D S 4 R = 8
EURL ENT 5.1 Quinu-dalfo-pristin, Q-D
2 <=16 - -
EURL ENT 5.2 Erythromycin, ERY
1 R >8 S = 4
EURL ENT 5.2 Streptomycin, STR R <=512 S <=64
EURL ENT 5.5 Quinu-dalfo-pristin, Q-D
2 <=8 - -
EURL ENT 5.6 Quinu-dalfo-pristin, Q-D S <=4 R = 8
EURL ENT 5.7 Erythromycin, ERY R >8 S = 1
EURL ENT 5.7 Quinu-dalfo-pristin, Q-D
2 <=8 - -
EURL ENT 5.7 Streptomycin, STR R >2048 S = 128
EURL ENT 5.7 Tetracycline, TET R >32 S <=1
EURL ENT 5.8 Quinu-dalfo-pristin, Q-D
2 <=8 - -
EURL ENT 5.2 Erythromycin, ERY
1 4 S = 4
EURL ENT 5.6 Ampicillin , AMP
3 8 S <=2
EURL ENT 5.2 Erythromycin, ERY
1 R 8 S = 4
EURL ENT 5.6 Streptomycin, STR S 128 R = 1024
12 EURL ENT 5.2 Erythromycin, ERY
1 R 16 S = 4 MIC
EURL ENT 5.1 Quinu-dalfo-pristin, Q-D
2 8 - -
EURL ENT 5.5 Quinu-dalfo-pristin, Q-D
2 8 - -
EURL ENT 5.6 Quinu-dalfo-pristin, Q-D S 4 R = 8
EURL ENT 5.7 Quinu-dalfo-pristin, Q-D
2 8 - -
EURL ENT 5.8 Quinu-dalfo-pristin, Q-D
2 4 - -
17 EURL ENT 5.2 Erythromycin, ERY
1 R >8 S = 4 MIC
EURL ENT 5.2 Erythromycin, ERY
1 R 13 S = 4
EURL ENT 5.2 Gentamicin, GEN R 9 S <=16
EURL ENT 5.2 Streptomycin, STR R 6 S <=64
EURL ENT 5.3 Streptomycin, STR R 6 S <=64
EURL ENT 5.4 Gentamicin, GEN R 11 S <=16
EURL ENT 5.4 Vancomycin, VAN S 16 R = 16
EURL ENT 5.5 Gentamicin, GEN R 10 S <=16
EURL ENT 5.6 Gentamicin, GEN R 9 S <=16
EURL ENT 5.6 Tetracycline, TET R 11 S <=1
EURL ENT 5.7 Gentamicin, GEN R 9 S <=16
EURL ENT 5.7 Streptomycin, STR R 6 S = 128
EURL ENT 5.8 Gentamicin, GEN R 9 S <=16
EURL ENT 5.2 Erythromycin, ERY
1 R 8 S = 4
EURL ENT 5.3 Erythromycin, ERY R 4 S = 2
EURL ENT 5.4 Ciprofloxacin , CIP R 8 S = 2
EURL ENT 5.6 Ciprofloxacin , CIP R 8 S = 1
EURL ENT 5.6 Streptomycin, STR S 32 R = 1024
EURL ENT 5.7 Ciprofloxacin , CIP R 8 S = 1
20 EURL ENT 5.1 Chloramphenicol, CHL S 32 R = 64 MIC
23 EURL ENT 5.6 Quinu-dalfo-pristin, Q-D S 4 R = 8 MIC
EURL ENT 5.1 Quinu-dalfo-pristin, Q-D
2 R 14 - -
EURL ENT 5.4 Vancomycin, VAN S 17 R = 16
EURL ENT 5.5 Quinu-dalfo-pristin, Q-D
2 R 13 - -
EURL ENT 5.6 Streptomycin, STR S 16 R = 1024
EURL ENT 5.7 Gentamicin, GEN R 12 S <=16
EURL ENT 5.7 Quinu-dalfo-pristin, Q-D
2 R 14 - -
EURL ENT 5.8 Chloramphenicol, CHL S 12 R = 64
EURL ENT 5.8 Quinu-dalfo-pristin, Q-D
2 R 16 - -
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
4
Method 
used for 
AST
EURL ENT 5.3 Ampicillin , AMP R 8 S = 4
EURL ENT 5.6 Streptomycin, STR S 16 R = 1024
33 EURL ENT 5.2 Erythromycin, ERY
1 R 8 S = 4 MIC
EURL ENT 5.1 Quinu-dalfo-pristin, Q-D
2 S 16 - -
EURL ENT 5.3 Quinu-dalfo-pristin, Q-D R 2 S = 2
EURL ENT 5.5 Quinu-dalfo-pristin, Q-D
2 S 8 - -
EURL ENT 5.7 Quinu-dalfo-pristin, Q-D
2 S 8 - -
EURL ENT 5.8 Quinu-dalfo-pristin, Q-D
2 S 8 - -
36 EURL ENT 5.2 Erythromycin, ERY
1 R 8 S = 4 MIC
37 EURL ENT 5.1 Chloramphenicol, CHL S 32 R = 64 MIC
EURL ENT 5.3 Tetracycline, TET S 64 R > 32
EURL ENT 5.8 Gentamicin, GEN R 128 S <=16
EURL ENT 5.2 Erythromycin, ERY
1 R 12 S = 4
EURL ENT 5.2 Streptomycin, STR R 11 S <=64
EURL ENT 5.4 Erythromycin, ERY S 17 R > 32
EURL ENT 5.4 Vancomycin, VAN S 23 R = 16
EURL ENT 5.8 Chloramphenicol, CHL S 18 R = 64
EURL ENT 5.2 Ampicillin , AMP R 8 S <=2
EURL ENT 5.2 Ciprofloxacin , CIP R 8 S = 1
EURL ENT 5.2 Tetracycline, TET R >16 S <=1
EURL ENT 5.4 Ciprofloxacin , CIP R >8 S = 2
EURL ENT 5.6 Ampicillin , AMP R 8 S <=2
EURL ENT 5.6 Ciprofloxacin , CIP R >8 S = 1
EURL ENT 5.7 Tetracycline, TET R 8 S <=1
EURL ENT 5.1 Quinu-dalfo-pristin, Q-D
2 16 - -
EURL ENT 5.2 Gentamicin, GEN
3 <=128 S <=16
EURL ENT 5.3 Gentamicin, GEN
3 <=128 S <=16
EURL ENT 5.4 Gentamicin, GEN R 256 S <=16
EURL ENT 5.5 Gentamicin, GEN
3 <=128 S <=16
EURL ENT 5.5 Quinu-dalfo-pristin, Q-D
2 16 - -
EURL ENT 5.6 Ampicillin , AMP R 16 S <=2
EURL ENT 5.6 Gentamicin, GEN
3 <=128 S <=16
EURL ENT 5.7 Gentamicin, GEN
3 <=128 S <=16
EURL ENT 5.7 Quinu-dalfo-pristin, Q-D
2 32 - -
EURL ENT 5.8 Gentamicin, GEN
3 <=128 S <=16
EURL ENT 5.8 Quinu-dalfo-pristin, Q-D
2 8 - -
EURL ENT 5.4 Ampicillin , AMP S 0.5 R > 32
EURL ENT 5.6 Streptomycin, STR S 128 R = 1024
EURL ENT 5.7 Streptomycin, STR R 1024 S = 128
39 MIC
40 DD
29 MIC
34 MIC
41 MIC
42 MIC
MIC46
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
4
Method 
used for 
AST
EURL ENT 5.1 Ampicillin , AMP R 14 S <=2
EURL ENT 5.1 Ciprofloxacin , CIP R 0 S = 1
EURL ENT 5.1 Linezolid, LZD R 15 S = 2
EURL ENT 5.1 Vancomycin, VAN R 11 S <=1
EURL ENT 5.2 Ampicillin , AMP R 11 S <=2
EURL ENT 5.2 Ciprofloxacin , CIP R 11 S = 1
EURL ENT 5.2 Erythromycin, ERY
1 R 11 S = 4
EURL ENT 5.2 Gentamicin, GEN R 10 S <=16
EURL ENT 5.2 Linezolid, LZD R 19 S = 2
EURL ENT 5.2 Streptomycin, STR R 0 S <=64
EURL ENT 5.3 Ampicillin , AMP R 10 S = 4
EURL ENT 5.3 Ciprofloxacin , CIP R 14 S <=0.5
EURL ENT 5.3 Erythromycin, ERY R 12 S = 2
EURL ENT 5.3 Gentamicin, GEN R 10 S <=16
EURL ENT 5.3 Linezolid, LZD R 19 S = 2
EURL ENT 5.3 Streptomycin, STR R 0 S <=64
EURL ENT 5.4 Chloramphenicol, CHL R 12 S = 16
EURL ENT 5.4 Ciprofloxacin , CIP R 11 S = 2
EURL ENT 5.4 Gentamicin, GEN R 10 S <=16
EURL ENT 5.4 Linezolid, LZD R 19 S = 2
EURL ENT 5.5 Ampicillin , AMP R 14 S <=2
EURL ENT 5.5 Ciprofloxacin , CIP R 15 S <=0.5
EURL ENT 5.5 Gentamicin, GEN R 11 S <=16
EURL ENT 5.5 Linezolid, LZD R 18 S = 1
EURL ENT 5.5 Vancomycin, VAN R 13 S = 2
EURL ENT 5.6 Ampicillin , AMP R 0 S <=2
EURL ENT 5.6 Ciprofloxacin , CIP R 0 S = 1
EURL ENT 5.6 Gentamicin, GEN R 11 S <=16
EURL ENT 5.6 Linezolid, LZD R 17 S = 1
EURL ENT 5.6 Vancomycin, VAN R 14 S <=1
EURL ENT 5.7 Ampicillin , AMP R 15 S <=2
EURL ENT 5.7 Ciprofloxacin , CIP R 11 S = 1
EURL ENT 5.7 Erythromycin, ERY R 12 S = 1
EURL ENT 5.7 Gentamicin, GEN R 11 S <=16
EURL ENT 5.7 Linezolid, LZD R 17 S = 2
EURL ENT 5.7 Streptomycin, STR R 0 S = 128
EURL ENT 5.7 Vancomycin, VAN R 14 S = 2
EURL ENT 5.8 Ampicillin , AMP R 15 S <=2
EURL ENT 5.8 Ciprofloxacin , CIP R 12 S = 1
EURL ENT 5.8 Gentamicin, GEN R 12 S <=16
EURL ENT 5.8 Linezolid, LZD R 17 S = 2
EURL ENT 5.8 Vancomycin, VAN R 13 S <=1
1
, not included in the evaluation report (please refer to paragraph 3.2.1)
3
, not included in the evaluation report because no interpretation was reported by the participant
2
, not included in the evaluation report because there are no recommendations for quinupristin-dalfopristin susceptibility testing in E. 
faecalis  (please refer to protocol, Appendix 4) 
4
, expected values were not calculated for disk diffusion method and participants performing disk diffusion were invited to apply the 
interpretive breakpoins routinely used in their laboratories
54 DD
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
2
Method 
used for 
AST
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.2 Sulfamethoxazole, SMX R 512 S <=32
EURL ST 5.1 Ciprofloxacin, CIP
1 S 22.43 R = 2
EURL ST 5.8 Methicillin resistant Neg Pos
EURL ST 5.1 Ciprofloxacin, CIP
1 S <=1 R = 2
EURL ST 5.2 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.3 Gentamicin, GEN R >16 S <=0.25
EURL ST 5.3 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.4 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.7 Sulfamethoxazole, SMX R <=256 S <=32
EURL ST 5.8 Sulfamethoxazole, SMX R >512 S <=32
11 EURL ST 5.1 Ciprofloxacin, CIP
1 S 0.5 R = 2 MIC
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.2 Cefoxitin, FOX R 8 S = 4
EURL ST 5.1 Ciprofloxacin, CIP
1 S 23 R = 2
EURL ST 5.1 Sulfamethoxazole, SMX S 15 R = 512
18 EURL ST 5.1 Ciprofloxacin, CIP
1 S 22 R = 2 DD
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.2 Sulfamethoxazole, SMX R 512 S <=32
EURL ST 5.2 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.3 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.1 Sulfamethoxazole, SMX S 128 R = 512
EURL ST 5.1 Cefoxitin, FOX S 4 R = 8
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
23 EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2 MIC
26 EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2 MIC
29 EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2 MIC
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.2 Chloramphenicol, CHL S 8 R > 64
EURL ST 5.2 Erythromycin, ERY S <=0.25 R > 16
EURL ST 5.2 Penicillin, PEN S <=0.12 R > 16
EURL ST 5.3 Trimethoprim, TMP R 4 S = 1
EURL ST 5.8 Streptomycin, STR S >32 R > 64
36 EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2 MIC
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.1 Sulfamethoxazole, SMX S 128 R = 512
EURL ST 5.1 Ciprofloxacin, CIP
1 S 1 R = 2
EURL ST 5.2 Trimethoprim, TMP R 4 S = 1
EURL ST 5.6 Penicillin, PEN S 0.5 R = 0.5
EURL ST 5.1 Ciprofloxacin, CIP
1 S 28 R = 2
EURL ST 5.1 Gentamicin, GEN S 15 R > 16
EURL ST 5.1 Tetracycline, TET S 16 R = 32
EURL ST 5.4 Tetracycline, TET S 16 R = 32
EURL ST 5.6 Tetracycline, TET S 21 R = 8
EURL ST 5.7 Tetracycline, TET S 16 R > 32
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
2
Method 
used for 
AST
EURL ST 5.2 Gentamicin, GEN R 4 S <=0.25
EURL ST 5.2 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.2 Tetracycline, TET R 2 S <=0.5
EURL ST 5.2 Trimethoprim, TMP R 8 S = 1
EURL ST 5.3 Sulfamethoxazole, SMX R >512 S <=32
EURL ST 5.3 Tetracycline, TET R 2 S <=0.5
EURL ST 5.3 Trimethoprim, TMP R 16 S = 1
EURL ST 5.4 Trimethoprim, TMP R 16 S = 1
EURL ST 5.5 Erythromycin, ERY R 4 S = 0.5
EURL ST 5.6 Sulfamethoxazole, SMX R 256 S <=32
EURL ST 5.6 Trimethoprim, TMP R 16 S <=0.5
46 EURL ST 5.1 Chloramphenicol, CHL R 8 S = 4 MIC
EURL ST 5.1 Ciprofloxacin, CIP
1 S 24 R = 2
EURL ST 5.5 Cefoxitin, FOX S 17 R = 16
EURL ST 5.8 Cefoxitin, FOX S 17 R = 16
1
, not included in the evaluation report (please refer to paragraph 3.2.2)
41 MIC
2
, expected values were not calculated for disk diffusion method and participants performing disk diffusion were invited to apply the 
interpretive breakpoins routinely used in their laboratories
54 DD
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
2
Method 
used for 
AST
1 EURL EC 5.7 Streptomycin, STR R 16 S <=8 MIC
EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1
EURL EC 5.6 Ciprofloxacin, CIP S 0.06 R = 0.06
EURL EC 5.8 Trimethoprim, TMP R 4 S <=1
6 EURL EC 5.4 Ceftazidime, CAZ1 S <=0.5 R = 1 MIC
9 EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1 MIC
EURL EC 5.1 Nalidixic acid, NAL R 13 S = 16
EURL EC 5.4 Ceftazidime, CAZ1 S 28 R = 1
EURL EC 5.4 Nalidixic acid, NAL R 14 S = 16
EURL EC 5.6 Ciprofloxacin, CIP S 30 R = 0.06
EURL EC 5.8 Cefotaxime, CTX S 29 R = 1
EURL EC 5.8 Ceftazidime, CAZ S 26 R = 2
EURL EC 5.1 Nalidixic acid, NAL R 11 S = 16
EURL EC 5.4 Ceftazidime, CAZ1 S 27 R = 1
EURL EC 5.4 Nalidixic acid, NAL R 14 S = 16
EURL EC 5.5 Ceftazidime, CAZ S 26 R = 4
EURL EC 5.8 Cefotaxime, CTX S 30 R = 1
EURL EC 5.8 Ceftazidime, CAZ S 28 R = 2
16 EURL EC 5.8 Trimethoprim, TMP R 4 S <=1 MIC
EURL EC 5.1 Nalidixic acid, NAL R 32 S = 16
EURL EC 5.8 Trimethoprim, TMP R 4 S <=1
EURL EC 5.1 Ciprofloxacin, CIP S 28 R = 0.5
EURL EC 5.4 Ceftazidime, CAZ1 S 27 R = 1
EURL EC 5.4 Ciprofloxacin, CIP S 22 R = 0.5
EURL EC 5.8 Cefotaxime, CTX S 28 R = 1
EURL EC 5.8 Ceftazidime, CAZ S 26 R = 2
EURL EC 5.1 Nalidixic acid, NAL R 16 S = 16
EURL EC 5.3 Ciprofloxacin, CIP S 0.032 R = 0.25
EURL EC 5.4 Ciprofloxacin, CIP S 0.002 R = 0.5
EURL EC 5.6 Ciprofloxacin, CIP S 0.032 R = 0.06
EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1
EURL EC 5.8 Trimethoprim, TMP R 4 S <=1
EURL EC 5.4 Chloramphenicol, CHL R >64 S = 4
EURL EC 5.4 Nalidixic acid, NAL R 64 S = 16
EURL EC 5.5 Chloramphenicol, CHL R 64 S = 4
EURL EC 5.5 Ciprofloxacin, CIP R 0.25 S <=0.015
EURL EC 5.5 Gentamicin, GEN R 16 S = 1
EURL EC 5.5 Nalidixic acid, NAL R 64 S <=4
EURL EC 5.5 Streptomycin, STR R 128 S <=8
EURL EC 5.5 Sulfamethoxazole, SMX R 1024 S <=64
EURL EC 5.5 Tetracycline, TET R 32 S <=2
EURL EC 5.5 Trimethoprim, TMP R 32 S <=1
EURL EC 5.6 Cefotaxime, CTX R 4 S <=0.12
EURL EC 5.6 Ceftazidime, CAZ R 1 S = 0.064
EURL EC 5.1 Streptomycin, STR S 128 R > 128
EURL EC 5.3 Trimethoprim, TMP S <0.5 R > 32
EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1
23 EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1 MIC
25 EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1 MIC
26 EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1 MIC
29 EURL EC 5.1 Ceftazidime, CAZ R 8 S = 0.25 MIC
30 EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1 MIC
32 EURL EC 5.4 Ceftazidime, CAZ1 S <=0.5 R = 1 MIC
EURL EC 5.1 Nalidixic acid, NAL R 32 S = 16
EURL EC 5.4 Nalidixic acid, NAL R >16 S = 16
EURL EC 5.6 Chloramphenicol, CHL S 32 R = 32
EURL EC 5.8 Trimethoprim, TMP R 4 S <=1
33 MIC
20 MIC
21 MIC
22 MIC
17 MIC
18 DD
19 MIC
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Laboratory 
ID
Strain Antimicrobial Obtained 
interpretation
Obtained value 
(µg/ml if MIC; 
mm if DD)
Expected 
interpretation
Expected 
MIC 
(µg/ml)
2
Method 
used for 
AST
EURL EC 5.4 Nalidixic acid, NAL R 32 S = 16
EURL EC 5.6 Ceftazidime, CAZ R 1 S = 0.064
36 EURL EC 5.8 Trimethoprim, TMP R 4 S <=1 MIC
EURL EC 5.1 Ceftazidime, CAZ R 2 S = 0.25
EURL EC 5.1 Trimethoprim, TMP R 1 S <=1
EURL EC 5.3 Ceftazidime, CAZ R 1 S = 0.25
EURL EC 5.7 Ceftazidime, CAZ R 1 S = 0.125
EURL EC 5.1 Ciprofloxacin, CIP S 32 R = 0.5
EURL EC 5.1 Streptomycin, STR S 12 R > 128
EURL EC 5.1 Tetracycline, TET S 12 R > 32
EURL EC 5.2 Gentamicin, GEN S 18 R = 16
EURL EC 5.2 Tetracycline, TET S 12 R > 32
EURL EC 5.4 Ceftazidime, CAZ1 S 24 R = 1
EURL EC 5.5 Ceftazidime, CAZ S 20 R = 4
EURL EC 5.6 Chloramphenicol, CHL S 19 R = 32
EURL EC 5.6 Ciprofloxacin, CIP S 32 R = 0.06
EURL EC 5.6 Gentamicin, GEN S 15 R = 16
EURL EC 5.6 Nalidixic acid, NAL S 16 R = 32
EURL EC 5.7 Ciprofloxacin, CIP R 28 S < 0.015
EURL EC 5.8 Cefotaxime, CTX S 30 R = 1
EURL EC 5.8 Ceftazidime, CAZ S 26 R = 2
41 EURL EC 5.4 Ceftazidime, CAZ1 S 1 R = 1 MIC
EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1
EURL EC 5.6 Ciprofloxacin, CIP S 0.06 R = 0.06
EURL EC 5.8 Trimethoprim, TMP R 8 S <=1
EURL EC 5.4 Ceftazidime, CAZ1 S 0.5 R = 1
EURL EC 5.6 Ciprofloxacin, CIP S <=0.125 R = 0.06
EURL EC 5.7 Ampicillin,Â AMP R 64 S = 4
EURL EC 5.8 Streptomycin, STR R 128 S <=8
EURL EC 5.8 Tetracycline, TET R 64 S <=2
EURL EC 5.8 Trimethoprim, TMP R >32 S <=1
EURL EC 5.1 Ciprofloxacin, CIP S 23 R = 0.5
EURL EC 5.2 Florfenicol, FFN R 11 S = 4
EURL EC 5.2 Gentamicin, GEN S 24 R = 16
EURL EC 5.3 Ciprofloxacin, CIP S 23 R = 0.25
EURL EC 5.4 Ceftazidime, CAZ1 S 23 R = 1
EURL EC 5.4 Ciprofloxacin, CIP S 23 R = 0.5
EURL EC 5.4 Florfenicol, FFN R 10 S = 8
EURL EC 5.4 Gentamicin, GEN S 26 R >= 16
EURL EC 5.5 Ceftazidime, CAZ S 22 R = 4
EURL EC 5.6 Ciprofloxacin, CIP S 26 R = 0.06
EURL EC 5.6 Florfenicol, FFN R 11 S = 8
EURL EC 5.6 Gentamicin, GEN S 25 R = 16
EURL EC 5.7 Florfenicol, FFN R 15 S = 8
EURL EC 5.8 Ceftazidime, CAZ S 23 R = 2
EURL EC 5.8 Ciprofloxacin, CIP S 17 R = 2
1, not included in the evaluation report (please refer to paragraph 3.2.3)
54 DD
2, expected values were not calculated for disk diffusion method and participants performing disk diffusion were invited to apply the 
interpretive breakpoins routinely used in their laboratories
40 DD
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46 MIC
34 MIC
39 MIC
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